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Abstract 
 
Background: Pancreatic cancer remains a highly aggressive and not curable cancer in spite of the 
ample research in the last decades. Since conventional treatment approaches have not satisfactory 
effects because they don’t result in a significant improvement of the disease outcome, an effective 
research system is still strongly needed, in order to accurately predict the clinical efficacy of novel 
compounds developed for pancreatic cancer treatment.  
Aim: the aim of the current study is to contribute to the generation of a complete and 
straightforward system useful for the identification and pre-clinic screening of novel drug for the 
treatment pancreatic cancer. This system should provide the techniques, the protocols and a 
pancreatic cancer model suitable firstly for in vitro high-throughput compounds screening and then 
for in vivo validation of the selected molecules.  
Results: findings previously obtained in our laboratory have already demonstrate potential stem-
like behavior of Panc-1 cells growing as 3-dimensional spheres (Panc1-spheres), isolated from 
adherent Panc-1 cell line. In this study we continued with the in vivo characterization of Panc-1 
spheres because we used them as pancreatic cancer cell line model in the compounds screening 
system we are generating. So, we performed subcutaneus and orthotopical injections in nude mice 
with adherent Panc1 and Panc1-spheres cells. Tumor growths were followed using MRI. In order to 
deepen the characterization of Panc1-spheres, we also studied EMT on tumors derived from this 
experiment such as in vitro in both cell lines. Moreover, we observed that an improvement of 
imaging strategies was actually needed, in order to better control above all the formation of small 
masses as metastasis and early primary tumors, since MRI was not sufficient when used alone. For 
this reason, we also decided to focus our attention to the most important non-invasive small animal-
imaging modalities available today, in particular MRI, Micro-Ultrasound (US) and In Vivo Optical 
Imaging. Then, we correlated these techniques, arriving to the point to have an “imaging protocol”, 
able to offset some of the limitation of each modality when used alone, to be used in the compounds 
screening system we would like to generate.  
Conclusion: Our findings have demonstrated that the pancreatic cancer spheres are more than just 
cancer stem-like cells. Our mouse model, established with Sphere-growing cells, may be used for 
the testing of novel compounds specifically designed  to target  this stem-like compartment, 
resistant to standard chemotherapies. A combined imaging approach, with combine MRI, Optical 
imaging and US, in this contest become extremely important, in order to follow primary tumor sizes 
and metastasis detection before and after the treatment with novel compounds. 
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Abstract (italiano) 
 
Presupposti: nonostante gli enormi sforzi della ricerca per lo studio del carcinoma del pancreas, a 
tutt’oggi questo tumore aggressivo rimane incurabile e necessita di terapie mirate che garantiscano 
un miglioramento concreto della qualità della vita dei pazienti. Pertanto, è forte il bisogno di creare 
un sistema efficace e mirato all’identificazione di nuovi composti per la cura del cancro del 
pancreas. 
Scopo: lo scopo di questo lavoro è quello di contribuire alla generazione di un sistema che porti 
selezione di nuovi composti per il trattamento del carcinoma pancreatico. Questo sistema include 
tecniche, protocolli e un modello cellulare e animale di tumore del pancreas indispensabili per 
testare in vitro un alto numero di composti e per la successiva validazione in vivo dei composti 
selezionati.  
Risultati: nel corso di questo lavoro, abbiamo innanzitutto completato la caratterizzazione delle 
Panc1-sfere, che sono cellule tumorali presentanti caratteristiche di staminalità, precedentemente 
isolate nel nostro laboratorio dalla linea cellulare Panc1. Tali cellule coincidono con la 
subpopolazione cellulare più chemoresistente a numerosi composti già in uso clinico, pertanto sono 
ritenute essere il modello cellulare più indicato per la selezione di nuovi farmaci sia in vitro che in 
vivo. Al fine di studiare il comportamento in vivo delle Panc1-sfere, dapprima abbiamo inoculato 
queste cellule in sede orto topica in topi immunodeficienti e seguito la crescita tumorale ortotopici 
tramite Risonanza Magnetica (RMI). I nostri risultati hanno dimostrato che le Panc1-sfere 
rappresentano la subpopolazione più aggressiva perché crescono più velocemente rispetto alla 
controparte aderente, metastatizzano con maggiore frequenza e sono positive ai markers 
mesenchimali. Inoltre, abbiamo osservato che la RMI non è in grado di rilevare masse che poi sono 
state trovate nel corso delle necropsie, pertanto abbiamo effettuato un secondo esperimento, 
utilizzando due tecniche di Imaging in più: l’ecografia e l’Imaging Ottico. I risultati dimostrano che 
l’utilizzo contemporaneo di più tecniche di Imaging è estremamente utile perché fornisce 
informazioni complementari garantendo una maggiore precisione soprattutto per seguire in vivo gli 
effetti dei composti che saranno selezionati dallo screening in vitro.  
Conclusione: i nostri risultati dimostrano che il tumore ortotopico generato inoculando le Panc1-
sfere è un buon modello che può essere usato nello validazione in vivo di nuovi composti 
potenzialmente in grado di curare questa malattia. Inoltre, proponiamo un protocollo combinato 
delle tre metodiche di Imaging che, considerando i limiti e i vantaggi di ciascuna, garantisce di 
monitorare la crescita tumorale in ogni sua fase, sempre nelle migliori condizioni.  
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Abbreviations 
 
BLI= Bioluminescence Imaging 
BSA= Bovine Serum Albumine 
CSC=Cancer Stem Cells   
CSM= Cancer Stem Cell Medium: DMEM+F-12 (1:1), 1X B27, Fungizone 1% 
Penicillin/Streptomycin, 5 mg/ml Heparin supplemented with 20 ng/ml EGF and FGF 
DM= Differentiation Medium: DMEM+F-12 (1:1)+1X B27, Fungizone, 1% 
Penicillin/Streptomycin, 1% FBS 
D-PBS= Dulbecco's Phosphate Buffered Saline solution without Ca++ and Mg++ 
EMT=Epithelial to Mesenchymal Transition 
GEM= Gemcitabine 
GR= Gemcitabine-resistence 
HGF= Hepatocyte Growth Factor 
IPMN= intraductal pancreatic mucinous neoplasm  
MCN= mucinous cystic neoplasm 
MET= Mesenchymal to Epithelial Transition 
Micro-CT= micro-computer tomography 
Micro-PET=micro-positron emission tomography 
Micro-SPECT= Single photon emission computed tomography 
Micro-MRI=micro-magnetic resonance imaging 
PanIN = pancreatic intraductal neoplasia  
PCSC= Pancreatic Cancer Stem Cells 
PDAC= Pancreatic ductal adenocarcinoma 
SDF1= Stromal Derived Factor 1 alpha 
SM= Standard Medium: RPMI+10%FBS+1% Penicillin/Streptomycin 
WST-1= (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-Benzene disulfonate 
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I. Introduction 
 
Pancreatic cancer is one of the most lethal human cancers with an overall survival rate of 3-5% and 
a median survival of less than 6 months. The short median survival is explained by the absence of 
early symptoms and lack of appropriate diagnostic tools for early detection. The cancer’s lethal 
nature results from its propensity to rapidly disseminate to the lymphatic system and distant organs, 
occurring in more than 80% of cases.  Metastasis to loco-regional lymph nodes or distant organ are 
one of the major features of pancreatic cancer and are typically already present at the time of 
diagnosis. This aggressive biology and resistance to conventional and targeted therapeutic agents 
leads to a typical clinical presentation of incurable disease at the time of diagnosis still today. Many 
efforts have been made in the past years, but conventional treatment approaches have little impact 
on the course of this aggressive neoplasm [1]. 
 
1.1 Pancreas anatomy and physiology 
The pancreas, an organ of endodermal derivation, is the key regulator of protein and carbohydrate 
digestion and glucose homeostasis (Fig. 1). The exocrine pancreas represents the 80% of the tissue 
mass of the organ; it is composed of a network of acinar and duct cells for the production and 
digestive zymogens into the gastrointestinal tract. The acinar cells, organized in functional units 
along the duct network, synthesize and secrete zymogens into the ductal lumen. Within the acinar 
units near the ducts there are the centroacinar cells. The endocrine pancreas regulates metabolism 
and glucose homeostasis through the secretion of hormones into the bloodstream and; it is 
composed of four specialized endocrine cell types organized together into clusters called Islets of 
Langherhans [2].  
 
 
 
 
Figure 1. Anatomy of the pancreas.  
(A) Anatomy of the pancreas  
(B) The major components of the 
pancreatic parenchyma on a histological 
level. At lower right is an islet of 
Langherhans, The asterisk is placed 
among acini, which are involved in 
secreting various digestive enzymes into 
the ducts (indicated by the solid arrow). 
(C)H&E- and immunohistochemical-
stained sections of pancreatic tissue. 
(Panel 1) An acinar unit in relationship to 
the duct. (Panel 2) Acinar units. (Panel 3) 
Islet of Langerhans. (Panel 4) A 
centroacinar cell. (Panel 5) Ductal cells.  
(D) Representation of an acinar unit. 
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The pancreas arises from dorsal and ventral buds in the anterior endoderm, and during embryonic 
specialization a critical event is the repression of Sonic Hedgehog (Shh). This event results in the 
expression of the pancreatic homeobox transcriptor factor Pdx1 in the nascent pancreatic bud. 
Multipotent Pdx1+ cells are maintained in an undifferentiated state by Notch signaling (Fig. 2). 
Following Notch repression, Pdx1 progenitor cells are capable of differentiating into distinct 
pancreatic lineage, the three functional compartments of the pancreas, acinar, ductal and endocrine.  
 
Figure 2. Cell differentiation program in the pancreas  
 
There is a spectrum of distinct pancreatic malignancies with histological and molecular features that 
resemble the characteristics of the various normal cellular constituents. These multiple tumor types 
and hallmark features are summarized in Table 1. 
 
 
 
Metastatic pancreatic tumors are characterized by highly chemoresistance, in fact response rate to 
multiple classes of agents including antimetabolites is less than 20%. Gemcitabine is the standard 
treatment for metastatic pancreatic cancer, replacing 5-Fluorouracil thanks to its clinical 
(Hezel et al, 2006, Genes and Devel.) 
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improvements of diminishing the common debilitating symptoms. However, Gemcitabine, given 
alone or in combination with other chemotherapeutic agents (Table 2), opens the possibility of 6-
month in median survival; for this reason, the research of a effective treatment is the most important 
challenge and aim in clinical oncology up to now. 
 
Table 2. Therapeutic approach for pancreatic cancer 
 
 
 
1.2 Morphological characteristics of Pancreatic ductal adenocarcinoma. 
Pancreatic ductal adenocarcinoma (PDAC), so called because of its histological resemblance to 
normal ducts. PDAC commonly arises in the head of the pancreas with infiltration into surrounding 
tissues including lymphatics, spleen, and peritoneal cavity, and with metastasis to the liver and 
lungs. The disease is characterized by the presence of a dense stroma of fibroblasts and 
inflammatory cells, termed desmoplasia. Moreover, pancreatic stellate cells, a subpopulation of 
(Hezel et al, 2006, Genes and Devel.) 
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cells in the normal pancreas with fibroblast characteristics, have been observed in experimental 
models to respond to pancreatic injury and may contribute to the desmoplastic response in the 
setting of cancer [3]. PDAC primarily exhibits a glandular pattern with duct-like structures and 
varying degrees of cellular atypia and differentiation. Less common subtypes of PDAC include 
colloid, adenosquamous, or sarcomatoid histology.  
The three known precursor lesions are pancreatic intraductal neoplasia (PanIN), intraductal 
pancreatic mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN). 
Of these precursor lesions, the most common and extensively studied is PanIN, which is found in 
the smaller-caliber pancreatic ducts. Summarizing, PanINs are microscopic lesions in the smaller 
(less than 5 mm) pancreatic ducts; it is characterized by a spectrum of divergent morphological 
alterations localized into normal ducts showing graded stages of increasingly dysplastic growth [4]. 
PanINs are graded from stages I to III: the earliest one is characterized by the appearance of a 
columnar, mucinous epithelium and with increasing architectural disorganization and nuclear atypia 
through stages II and III (Fig. 3). PanIN I (divided in I-A and I-B) shows flat epithelial lesions 
composed of tall columnar cells with basally located nuclei and abundant supranuclear mucin. The 
nuclei appear small and round to oval in shape and ductal hyperplasia emerges. The high-grade 
PanINs ultimately transform into frank PDAC and is characterized by evidence of areas of invasion 
beyond the basement membrane. Mitosis are abnormal.  
Several molecular profiling studies have subsequently reinforced the PanIN-to-PDAC progression 
model through documentation of an increasing number of gene alterations in higher grade PanIN 
(see Section 1.3). 
Less common precursor lesions are MCNs and IPMNs. MCNs are large mucin-producing epithelial 
cystic lesions that harbor a distinctive ovarian-type stroma with a variable degree of epithelial 
dysplasia and focal regions of invasion. IPMNs resemble PanINs at the cellular level but grow into 
larger cystic structures. Of interest, two subtypes of invasive cancer have been found in association 
with IPMNs; typical PDAC, and a colloid type characterized by copious mucin production.  
Among IPMNs and MCNs, both common and distinct molecular events in comparison with PanINs 
have been described, suggesting that each precursor lesion may reflect variations on a common 
theme of malignant transformation of the duct.  
Expression profiling has revealed several up-regulated genes commonly associated with PanINs, 
IPMNs, and PDAC; however, how these PDAC precursor lesions relate to each other, their 
common or separate cellular origins, and whether each type leads to distinct molecular and 
biological PDAC subtypes remain to be fully explored. 
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Figure 3. Progression model for pancreatic cancer. The majority of pancreatic cancer is thought to 
develop through a series of hyperplastic and dysplastic ductal lesions termed pancreatic 
intraepithelial neoplasia (PanIN). 
 
 
1.3 Molecular genetics of PDAC 
Analyzing evolution of PDAC, a defined set of genetic lesions have been provided, often 
implicating known cancer genes and classical cancer signaling pathways. These molecular events 
have been linked with defined histopathologic stages of PDAC progression (Fig. 3). Pancreatic 
cancer is associated with a high rate of inactivation of three tumor suppressor genes: TP53, 
p16INK4A, and SMAD4. The p53 nuclear protein activates transcription of a cyclin kinase inhibitor 
p21WAF1/CIP1. Following genomic stress, inappropriate growth factor stimulation or expression of 
oncogenic ras [5] increased expression of p53, and thus p21WAF1/CIP1 resulted in inactivation of 
specific CDK/cyclin complexes and braking or termination of the cell cycle so that DNA repair or 
apoptosis can occur. Loss of these functions by inactivation or alteration of the p53 gene have been 
reported in more than 50% of pancreatic cancers.  
 
The p16INK4A/p14ARF (also known as CDKN2A) locus on chromosome 9q21 encodes these two 
tumor suppressor genes. Loss of function by mutation, deletion or promoter hypermethylation 
occurs in 80% to 95% of sporadic cancers [6]. The p16INK4A gene regulates cell cycle progression 
by inhibition of cyclin D/CDK4/6 complexes and thus inhibition of Rb phosphorylation. The 
interaction of p14ARF with MDM2 leads to p53 activation. In pancreatic-cancer development, 
inactivation of p16INK4A seems to be of greater importance than inactivation of p14ARF since 
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germline and sporadic mutations have been identified that target p16INK4A and leave p14ARF intact. 
Recent studies indicates that inactivation of p16 leads to overexpression of pRB that is linked with 
chemoresistance [7]. 
 
SMAD4 (also known as DPC4) is deleted or mutated in more than 50% of pancreatic carcinomas 
[8]. The gene product is an intracellular mediator of the transforming growth factor beta (TGF-β) 
pathway that inhibits cell growth by inducing G1 arrest, but it also may have a role in angiogenesis. 
TGF-β is the prototypic member of a superfamily of secreted proteins, whose other members 
include the Bone Morphogenic Proteins (BMPs) and Activins. These growth factors signal through 
serine/threonine kinase receptor complexes that, upon ligand binding, phosphorylate receptor-
regulated Smad  proteins (SMAD2, SMAD3, and the obligate binding partner SMAD4) regulating a 
variety of cellular functions including proliferation, differentiation, migration, and apoptosis.  
The importance of TGF-β signaling in pancreatic cancer is illustrated by the fact that 90% of tumors 
show loss of heterozygosity (LOH) at the SMAD4 locus, with 50% of PDAC having either 
homozygous deletion or mutational inactivation of the second allele.  
The loss of SMAD4 in PDAC may have a primary role in modulating the interaction of the tumor 
with the microenvironment rather than in growth control of the tumor cells themselves.  
 
K-RAS, a member of the RAS family of GTP-binding proteins, mediates a wide variety of cellular 
functions such as proliferation, differentiation, and survival. Although RAS is a GTPase, its 
intrinsic activity is inefficient and requires GTPase activating proteins (GAPs) to promote GTP 
hydrolysis and attenuate downstream signaling. Activating K-RAS point mutations at codon 12 
(from GGT to GAT or GTT, and more rarely CGT) results in substitution of glycine with aspartate, 
valine, or arginine. These mutations are the first known genetic alterations, occurring sporadically 
in normal pancreas tissue, and are detected in ∼30% of early neoplasms with the frequency rising to 
nearly 100% in advanced PDAC (Fig. 4).  
Consistent with a central pathogenic role of the K-RASG12D mutation, many mice engineered with 
pancreas-specific expression of this activated K-RAS allele sustain classical PanIN lesions that can 
progress to PDAC in the appropriate tumor suppressor background.  
 
Focusing the attention to the connections between development and cancer, the cross roles of the 
Hedgehog and Notch signaling pathways in PDAC pathogenesis have recently been investigated. 
The mammalian Hedgehog family of secreted signaling proteins comprised of Sonic, Indian, and 
Desert Hedgehog (SHH, IHH, and DHH, respectively) regulates the growth and patterning of many 
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organs, including the pancreas, during embryogenesis [9]. The Hedgehog pathway is negatively 
regulated by the Patched (PTC) tumor suppressor protein, which inactivates the Smoothed protein 
(SMO). Hedgehog ligands engage the PTC transmembrane protein and disrupt inhibition of Smo, 
activating the Gli family of transcriptional regulators. Alterations that activate this pathway, 
including loss of PTC, activating mutations in SMO, and overexpression of GLI and HH proteins, 
have been implicated in a variety cancers, including pancreatic adenocarcinoma. Activation of the 
Hedgehog pathway has been implicated in both the initiation of pancreatic ductal neoplasia and in 
the maintenance of advanced cancers. SHH is absent from the normal adult pancreas, but is 
activated in PanINs, exhibiting a graded increase in progressively later-stage lesions and 
carcinomas; moreover,  its signaling seems to be necessary for tumor maintenance [9, 10].  
The role of SHH in pancreatic cancer development is one of the  investigation this study is based on 
(see Section 1.5). 
 
 
 
 
 
 
Figure 4. Histologic-genetic progression model for pancreatic cancer. 
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1.4 Cancer Stem Cells.  
Cells with stem cell characteristics have been identified in several solid tumors, like breast, colon or 
pancreas [1] and have been named ‘cancer stem cells’.  
This term first referred to a cancer cell able to produce tumors when injected into SCID mice, 
demostrating self-renewal properties and giving rise to other cell types in the tumor were 
xenografted into immunodeficient mice. This small population of undifferentiated cells with stem 
cell characteristics can perform asymmetrical division to replicate themselves, but also to create a 
committed progenitor cell at the same time, like normal stem cell population. 
Two general models to explain heterogeneity present in solid cancer cells have been suggested up to 
now. The first of them supposes that cancer cells of many different phenotypes have the same 
potential to proliferate extensively. 
Instead, according to the second cancer stem cells hypothesis, most cancer cells have only limited 
proliferative potential, but a subset of cancer cells, the cancer stem cells,  consistently proliferate 
extensively in clonogenic assays and can form new tumors on transplantation. Like their normal 
stem-cell counterparts, they are able to self-renewal and produce more differentiated cells without 
stem cells properties contemporaneously (Fig. 5).  This last model shown underlines  that just a 
distinct subset of cells is enriched for the ability to form new tumors, whereas most cells don’t 
possess this ability.  
This could be the reason why existing therapeutic approaches, thought  largely on the first model, 
failure; so, the second hypothesis is consider to be more accurate. 
        Figure 5. The cancer stem cells hypothesis. 
 
Conventional therapies kill mainly cells with limited proliferative potential. If the putative cancer 
stem cells are less sensitive to these therapies, then they will remain viable after therapy and can  re-
establish the tumor. By contrast, if therapies can be specifically targeted against cancer stem cells, 
they might more effectively kill the cancer stem cells, rendering the tumors unable to maintain 
themselves or grow again (Fig. 6).  
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Cancer stem cells may be responsible for tumor initiation, metastasis, and resistance to treatments; 
so, they are the cells to target to cure a cancer. 
 
 
Figure 6. Drugs and cancer stem cells 
 
 
 1.4.1 Pancreatic Cancer Stem cells  
Cancer stem cells were first identified in acute myelogenous leukemia by Dick and collegous, 
which isolated CD34+/CD38- leukemic stem cells from human acute myelogenous leukemia [11]. 
Subsequently, Li et al [12] investigated the relationship between cancer stem cells and pancreatic 
cancer progression. In that study, a subpopulation of highly tumorigenic cancer cells were 
identified, analyzing the expression on the cells surface of CD44, CD24 and epithelial-Specific 
antigen ESA, on the basis of prior work on breast cancer stem cells in which ESA+ CD24-CD44+ 
cells, capable to generate tumors histologically similar to primary breast cancer, were found [13]. 
Pancreatic cancer stem cells resulted triple-positive for the markers CD24, CD44, ESA, showing 
features typical of adult stem cells, such as ability to self-renew and activation of developmental 
pathway like Sonic Hedgehog pathway. Li and collegous performed also FACS-sorted cells from 
human pancreatic adenocarcinoma xenografts: cells were suspended in a Matrigel mixture and 
subcutaneously injected into immunocompromised NOD/SCID mice. Interestingly, pancreatic 
cancer cells with the CD44+ CD24+ ESA+ phenotype (which represented only 0.2–0.8% of 
pancreatic cancer cells) had a 100-fold increased tumorigenic potential compared to non-
tumorigenic cancer cells negative for the same markers. Moreover, the treatment with the 
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chemotherapeutic agent gemcitabine on these pancreatic tumor xenografts involved in enrichment 
of the CD44+ CD24+ ESA+ cell population. 
Thanks to characterization studies of cell surface markers associated with solid tumor stem cells, 
the stem cell markers’ list is long today. CD133, also known as prominin-1, has also been used to 
identify putative cancer stem cells in breast, brain, liver, colon, prostate, and pancreatic tumors [14]. 
It was first discovered as a marker of normal hematopoietic stem cells and later was found to mark 
stem/progenitor cells from a variety of tissues. Evidence for existence of CD133+ pancreatic cancer 
stem cells was first reported by Hermann et al. [15]: similar to Li et al., FACS approach was chosen 
to prospectively isolate and characterize CD133+ cells from primary pancreatic cancer patient tissue 
samples and tumor cell lines. They found that in the majority of patient’s samples, the capacity of 
cells to form primary tumors following orthotopic implantation in nude mice was limited to a 
subpopulation of CD133+ cells that were exclusively tumorigenic and highly resistant to standard 
chemotherapy (Gemcitabine). The CD133+ cells were serially passed, demonstrating self-renewal 
capacity and were able to generate tumor heterogeneity, producing differentiated non-tumorigenic 
progeny.  
Primary pancreatic tumors comprised a higher fraction of CXCR4+ cells that displayed increased 
migratory activity in vitro and, furthermore, correlated with metastatic disease in pancreatic cancer 
patients. CXCR4 is the receptor of the stromal cell-derived factor 1 (SDF-1), an important mediator 
in cell migration; for this reason, the positivity to CXCR4 is often investigated.  
Data produced by Hermann and collegous demonstrated that depletion of the CXCR4 subset of all 
CD133+ cells isolated from cells lines, such as highly metastatic human pancreatic cancer cell line 
L3.6pl or the cell line MiaPaca, completely inhibited the formation of spontaneous liver metastases, 
without affecting their tumorigenic potential. SDF-1 appeares to be the strongest inducer of 
migration for CD133+ cancer cells in vitro and this data  correlated well with what was found in 
metastasis’ patients. In these cell selected for their CD133+/ CXCR4+, the authors observed also 
the loss of cytokeratin, one of the first steps of the epithelial to mesenchymal transition (EMT) 
program (see Section 1.6). Authors defined a distinct subset of CD133+/CXCR4 + cells that 
localized to the invasive edge of pancreatic carcinomas and exhibited significantly stronger 
migratory activity in vitro than CD133+CXCR4- cells. Only CD133+CXCR4+ cells demonstrated in 
vivo metastatic activity to the liver. Moreover, pharmacological depletion of CD133+CXCR4+ cells 
by inhibition of the CXCR4 receptor profoundly reduced the metastatic potential of pancreatic 
tumors without altering their tumorigenic potential. These findings have important therapeutic 
implications, as the design of drugs that target the metastatic CSC would be envisaged to have a 
profound effect on patient survival.  
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As discussed previously, in Section 1.1,  therapies specifically targeting pancreatic cancer stem cells 
will likely be needed to result in total tumor eradication and prevention of metastasis. Because 
cancer stem cells possess many of the features of normal stem/progenitor cells, it will be important 
to determine if novel strategies may be effective in targeting cancer stem cells without interfering 
the activity of normal stem/progenitor compartment. Novel screens specifically designed to target 
cancer stem cells are available today; examples are DNA and tissue microarray analyses of tumors, 
that are widely used to identify cancer subtypes trying to improve diagnosis and treatment. The use 
of sphere formation assays in vitro as well as implantation and serial transplantation assays in vivo 
might be actually useful in the identification of agents that selectively kill cancer stem cells, 
improving the drug discovery in this field.  
An example of in vitro screening using selected cancer stem cells requires the use of a steroid-like 
compound cyclopamine that binds to and inhibits the SMO protein (G-protein-coupled receptor 
family protein of hedgehog signaling); it inhibits the growth of cells and tumors with activated 
Hedgehog signaling, even if cyclopamine alone is not capable of effectively diminishing the CSC 
pool until undetectable levels in vitro and in vivo [16]. Using  an orthotopic xenograft model,  
Feldmann et al. demonstrated that cyclopamine (in particular, the orally bioavailable small-
molecule Hedgehog inhibitor, IPI-269609) profoundly inhibited metastatic spread in combination 
with  gemcitabine, significantly reduceding the size of primary tumors at the same time [17].  
Moreover, in pancreatic cancer cell lines, inhibition of Hedgehog with cyclopamine has been shown 
to result in the downregulation of Snail and upregulation of E-cadherin [18]. This was consistent 
with the inhibition of epithelial-to-mesenchymal transition (EMT) and was mirrored by a reduction 
of in vitro invasive capacity of tumor cells.  
These findings suggest that, targeting the Hedgehog signaling, growth of cancer stem cells can be 
reduce strongly.  
 
 1.4.2 Cancer Stem cells and epithelial-mesenchymal transition.  
Metastasis is the predominant cause of lethality in cancer patients. However, looking to the cancer 
stem cells hypothesis discussed before and currently accepted,  not every cell in a tumor has the 
ability to metastasize to other organs. Metastatic potential depends on multiple factors that 
determine overall tumor cell growth, survival, angiogenesis and invasion and only a sub-set of 
tumor cells show these characteristics. The epithelial-mesenchymal transition (EMT) is considered 
to be a crucial event in the metastatic process, because the disruption of epithelial cell homeostasis 
and the acquisition of a migratory mesenchymal phenotype are required for distal tumor masses 
formation (see also section 1.6) [19]. To date, the classical view on the metastatic cascade follows 
18 
 
these steps: 1. EMT occurring in a subpopulation of tumor cells; 2. dissociation of tumor cells from 
primary tumor; 3. invasion of neighboring tissue; 4. intravasation; 5. transport through vessels 
surviving to anoikis; 6. extravasation from vessels; 7. establishment of migratory cells at a 
secondary anatomical site, probably in a state of “dormance” for a prolungate period of time; 8. 
growth of the mass. 
In many epithelial tumors, an EMT or loss of differentiation is frequently evident at the invading 
edge of the tumor and is probable to mediate cellular detachment in a limited number of cells. The 
EMT appears to be controlled by crucial pathways such as the Wnt and transforming growth factor 
β pathways, both of which can be aberrantly activated during neoplasia. Recent reports suggest that 
there may be a direct link between the EMT and acquisition of stem cell properties. Cells 
undergoing an EMT could conceivably be the precursors to metastatic cancer cells, perhaps even 
metastatic CSCs. CSCs may also have a role in the creation of a particular niche for metastasis 
probably because they often undergo to EMT program. Recently, the link between highly 
tumorigenic behavior, CSCs and EMT is strongly studied; it is possible that CD133+ cells, about 
which we discussed before, have undergone EMT explaing at the same time their highly metastatic 
phenotype. Several pathways that mediated stem cell self-renewal, like WNT, Shh and NOTCH, 
also play a role in EMT induction.  
Important findings by Shah and collegous [20] demonstrate the correlation between EMT and 
gemcitabine-resistant (GR) cells: they obtained resistant cells by culturing the pancreatic cancer cell 
lines L3.6pl and AsPC-1 in serially increasing concentrations of gemcitabine. Gemcitabine-resistant  
cells underwent distinct morphological changes, including spindle-shaped morphology, appearance 
of pseudopodia, and reduced adhesion characteristic of transformed fibroblasts. Moreover, these 
cells were more invasive and migratory. GR cells were increased in vimentin and decreased in E-
cadherin expression. Immunofluorescence and immunoblotting experiments revealed increased 
nuclear localization of total beta-catenin. These alterations point out the  epithelial-to-mesenchymal 
transition (EMT) in gemcitabine-resistent cells, which could coincide with CSCs. Infact, resistant 
cells were activated in the receptor protein tyrosine kinase, c-Met and increased in expression of the 
stem cell markers CD (cluster of differentiation) 24, CD44, and epithelial-specific antigen (ESA). 
Then, these emerging lines of evidence suggest the molecular and phenotypic association that occur 
between the acquisition of EMT, chemoresistence and crucial role of CSCs in metastatic behavior 
in cancer. The Notch Pathway is involved, as we have already said, in EMT during tumor 
development and is particularly associated in the switch of cells from polarized to motile invasive 
cells. The increased activation of members of this pathway (such as Notch-2 and Jagged-1) in GR 
cells reinforces this knowledge, and data coming from Shah and collegous underline also that  the 
19 
 
down-regulation of Notch signaling induces reversal of EMT to MET in GR cells [20] (see Section 
1.6). 
 
 
1.5 Characterization of Pancreatic Cancer Stem Cells: preliminary data of our 
laboratory. 
 
As descrive in section 1.4, it has become increasingly clear that many tumours contain a very small 
(2-5%) subpopulation of cells, called cancer stem-like cells (CSCs). Summarizing, CSCs stem cells’ 
properties were hypothesized to be more aggressively growing, are chemoresistant to a lot of 
molecules and present tumour metastatic capacity. 
CSCs are usually recognized by expression of their membrane protein expression profile (CD133, 
CD44, CD24 and ESA particularly). Moreover, previous observations have clearly demonstrated 
that CSCs have the ability to grow as cellular aggregates with spheroidal shape, called spheres 
(sph), in contrast to the adherent counterpart (adh). We capitalized this property, instead of 
separating stem marker-positive cells from negative ones, to obtain CSCs. 
To generate spheres, a panel of 8 well-established pancreatic cancer cell lines which grow like 
adherent cells were thus subjected to culture in CSCs medium (CSM), a serum-free medium 
supplemented with growth factors (EGF and FGF). It was previously been demonstrated that this 
colture conditions promote sphere-growing of cells. The 8 cell lines subjected to culture with CSM 
were: Panc-1, Psn-1, and Panc-2 (PancTu1) coming from primary tumors; CFPAC, Suit-2 Im, Suit-
2 Io, S2CP9 coming from liver metastasis, and T3M4 coming from Lymph node metastasis. The 
cells started to change their typical epithelial morphology within 24-36 hours from the incubation 
with CSM. Six cell lines, with the exception of PancTu1 and T3M4, developed spheres. 
The difference in behavior of spheres versus adherent cells was investigated in a panel of in vitro 
phenotypic assays and, in the current study, in a orthotopic mouse model. 
The results of the preliminary data confirmed the hypothesis that sphere growing cells not only 
display stem cell characteristics but can be considered as the aggressive subpopulation of pancreatic 
tumors. Preliminary data generated in our laboratory demonstrated the link between aggressiveness 
and stemness in sphere growing pancreatic tumor cells.  
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Figure 7. Pictures of Panc-1 spheres obtained from established adherent cells line cultured in CSM 
for four weeks 
 
 
The cells typically lost their rhomboidal epithelial shape and became floating cells or cell clusters. 
After 1 week, the floating spheroids were collected without disturbing the remaining adherent cells 
and were grown until they reached a sufficient density to be transferred to a 75 cm2 flask. After 
four weeks, a clear distinction between the cell lines that had the capability to form spheres and the 
ones that had not could be made. Six of the eight adherent cell lines (Panc-1, Psn1, CFPAC, Suit-2 
Im, Suit-2 Io and S2CP9) were classified as ‘capable to form spheres’ (Fig. 7).  
All works were focused on the characterization of Panc-1 cells. The most important characteristic of 
this cell line about its genetic profile are: mutation of Kras and p53 genes (+), deletion of p16 gene, 
DPC4/Smad, DCC and BRCA2 are wild type. The expression of the complete panel of stemness 
markers (CD24, CD44, ESA, CD133) was assessed in Panc-1 spheres and adherent cells both at the 
gene and protein levels using qRT-PCR and FACS technology, respectively. CD24 gene expression 
in Panc-1 spheres is 25-fold higher than in adherent cells. 
In order to assess whether pancreatic spheres were enriched in dedifferentiated cells, CK19 
labeling, a ductal marker routinely used as a differentiation marker in the diagnosis of pancreatic 
cancer, was performed on both sphere growing and adherent cells. CK19 was absent in spheres  
whereas 80–90% of the Panc-1 adherent cells showed CK19 positivity. 
To verify that PANC-1 sphere growing cells also display characteristic stem cell properties, typical 
stem cell functionalities such as self-renewal and multipotentiality was assessed.  
For self-renewal assay, Panc-1 spheres were dissociated into single cells and plated in a 96-well 
plate as a single cell per well. After seven to ten days only 16% of the single cells were able to 
produce second generation spheres; moreover, the newly formed spheres were morphologically 
more regular than the initial spheres. These observations confirmed that Panc-1 spheres contain a 
stem-enriched subpopulation of cells, potentially responsible for a more aggressive tumor behavior. 
The multipotentiality test was aimed at demonstrating that Panc-1 spheres when subjected to 
differentiating conditions results in an increase of Panc-1 differentiation markers from different cell 
Panc1 adherent cells Panc1 spheres growing cells 
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lineages. Cells were grown in chamber slides at a density of 100 cells/well in DM or in SM. After 
10 days, dissociated spheres were completely attached to the plastic slides and, compared to the 
Panc-1 adherent cells; they assumed mixed morphological shapes. For instance, some elongated 
cells were morphologically comparable to fibroblasts, whereas others were more epithelial-like. 
Specific markers of pancreatic development were selected in order to track the differentiation 
profile of Panc-1 spheres in differentiating conditions. As already described in Section 1.1, 
embryonic pancreatic epithelium gives rise to the three pancreatic cell types (endocrine, acinar and 
ductal cells); in both rodents and humans. In order to evaluate the multipotentiality, CK19, Pdx1 
and Isl-1 were chosen as markers of the different cell types. The observation that PANC-1 adherent 
cells are more differentiated than Panc-1 spheres was confirmed by the fact that the expression of 
both PDX1 (an early pancreatic progenitor cell marker) and Isl-1 (beta cell precursor marker) are 
inversely related to differentiation [22]. 
Panc-1 spheres are CK19 negative; 19 days after differentiation in DM, 30% of the cells became 
CK19 positive. In particular CK-19 positive cells were found to be fibroblast-like with epithelial 
shape. Since the adherent cells displayed even a higher CK19 positivity (up to 80-90%), these 
results may indicate that the adherent cells are more differentiated than Panc-1 spheres. 
The gene expressions of CXCR4, Osteopontin and Hedgehog signaling pathway components (e.g., 
Shh, Gli1, Ptc1), were analyzed both in Panc- 1 spheres and adherent cells. In fact, it has been 
demonstrated that there is a clear correlation between increased pancreas cancer metastatic potential 
and increased expression of proteins such as the chemokine receptor CXCR4 [15] and Osteopontin 
[23].  
CXCR4 is a chemokine receptor (GPCR). Upon binding of its natural ligand SDF-1, CXCR4 has 
been reported to be involved in cell migration, angiogenesis, proliferation and metastasis. 
Osteopontin (OPN), the natural ligand of CD44, was also reported to be involved in pancreatic 
metastasis.  
Spheres in comparison to adherent Panc-1 showed a 9 fold higher mRNA expression of CXCR4 
and 350-fold increase in osteopontin mRNA. The mRNA levels of the Hedgehog pathway 
components Shh, Gli1 and Ptch were investigated in spheres vs adherent cells in order to assess 
hedgehog pathway activation at the receptor level (Shh) and downstream the receptor activation 
(Gli1 and Ptch). FACS analysis demonstrated that Panc-1 spheres also displayed an increased 
membrane expression of CXCR4 when compared to their adherent counterpart Indeed, the 
percentage of membrane CXCR4 expression increased from 6,20 % in adherent cells to 19,40% in 
cells derived from spheres. 
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In order to assess the growth rate of Panc-1 spheres compared to the adherent cells, the WST-1 
proliferation assay was performed. The adherent cells were grown in 10% FBS and 1% FBS 
whereas the spheres were grown in CSM. Although the growth rate during the first seven days of 
the experiment was the same in all three conditions, after more than 7 days the Panc-1 spheres 
started to grow significantly faster than the adherent cells. 
The chemoresistance of the Panc-1 sphere-growing vs adherent cells was assessed by incubating the 
cells for 7 days with increasing concentrations of GEM. Subsequently the growth reducing capacity 
of GEM was quantified using WST-1 proliferation assay.  
As depicted in Figure 8, at 10 µM of GEM (red arrow), all adherent cells were killed, whereas 10% 
of the sphere population survived to Gemcitabine up to 200 µM. Preliminary results obtained in our 
laboratory confirmed the observation of Gou et al. who reported that Panc- 1 spheres contain a 
chemoresistant, side population of 15%. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 8. Proliferation profile (WST-1) of sphere-growing vs adherent Panc-1 upon incubation 
with increasing concentrations of GEM (Figure kindly provided by Dr. Dandrea M.C.P.) 
 
To validate the Panc-1 sphere model the pancreatic tumour standard of care treatment Gemcitabine, 
was used. 50 female athymic mice were divided in two groups: 25 mice were injected with 107 
Panc-1 adherent cells and 25 mice with the same number of Panc-1 spheres. One week after the 
injection, tumour growth was monitored. Mice injected with Panc-1 spheres showed a bigger 
tumour mass than adherent cells: the average tumour mass of spheres was 177 mm3 compared to 
the tumour mass derived from adherent cells which was 77 mm3. This observation can be 
Gemcitabina
0
10
20
30
40
50
60
70
80
90
100
110
0 0,03 0,1 0,3 1 3 10 30 50 200
[Gem] (µM)
%
 
ce
lls
 
su
rv
iv
ed
Adh
Sph
23 
 
considered as a clear indication that Panc-1 spheres are enriched in tumour-initiating cells and 
confirms the in vitro observation that Panc- 1 spheres grow faster. Only when the tumors of all 
groups reached a similar tumour mass (range of 150-200 mm3), randomization was performed (two 
groups of 10 mice each with a comparable tumour size) and GEM treatment was started. 
Gemcitabine was administered by IP to 10 mice at the dose of 100 mg/kg following a scheduling 
treatment which had been previously published (day 7, 10, 13, 16, 19, 22, 25, 28). The 
corresponding control mice were treated with the vehicle only (physiologic solution) . Tumour 
volume and body weight were monitored twice a week. A minor decrease in body weight loss 
(10%) due to GEM treatment was observed. 
GEM demonstrated a significant tumour growth reduction after 22 days. Moreover, the in vivo 
data endorse the in vitro as well as the clinical data, demonstrating that GEM does not lead to a 
complete eradication of the tumour. 
After establishing the difference in stemness markers and CXCR4 expression between spheres and 
adherent cells, a transwell migration assay was performed in order to assess the migrating capability 
of spheres vs adherent cells. Only SDF-1, the ligand of CXCR4, induced a significant difference in 
the migration capacity between spheres and adherent cells while had no noticeable effect on the 
migration of adherent cells.  
Finally, findings obtained in our laboratory demonstrated that we have at our disposal a new 
pancreatic cancer model system that definitely better mimics certain clinical features both in vitro 
and in vivo settings. 
 
 
1.6 Epithelial-mesenchymal transition (EMT). 
The metastatic mechanism is a multistep process. Resistance to anoikis has been shown to promote 
metastasis, since tumor cells can enter and disseminate into the bloodstream and can survive even 
losing their cell-cell contacts. Anoikis suppression is an important prerequisite for tumor cells to 
metastasize to distal sites. Different integrin complexes are linked with member of ECM ; integrin 
activation protect from anoikis in that way.  To allow these change to be done, cells must be able to 
detach from the junctions that connect them to the neighboring ones, change their shape and 
polarity, delaminate and migrate. The event responsible for such profound modifications is the 
Epithelial–mesenchymal transition (EMT); it occurs in 90% of human tumor and could be first 
identified like a change in cell morphology. Epithelial cells are characterized by a highly baso-
apical polarization essential for their biological role, such as vesicle transport or protective barrier. 
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The epithelial cell basolateral surface are closely associated with neighboring cells thanks to 
membrane-associated specialized junctions [19].  
Mesenchymal cells display loss of baso-apical polarization and are characterized by front-rear 
polarization necessary for cell migration. Moreover, a distinct organization of actin cytoskeleton 
enhances  communication with the extracellular matrix; so, in contrast with ephitelial, mesenchymal 
cells become flat and spindle-shaped, showing growth factors production in collaboration with 
surrounding stroma.  
 
 
Figure 9. From Epithelial to Mesenchymal cells and back to ephitelial phenotype (MET): main 
steps. 
 
While the main type of adhesion system in epithelia is E-cadherin mediated cell-cell interaction that 
stabilises the multicellular architecture, the adhesion system in mesenchymal cells comprises 
dynamic integrin-mediated cell-matrix interactions that allow the motility of single elements.  
E-cadherin is a transmembrane glycoprotein with an extracellular domain that interacts with the E-
cadherin molecule on adjacent cells, and an intracellular domain associated with a multiprotein 
complex comprising α-, β- and p120 catenin.  
β-catenin binds to the cytoplasmic domain of E-cadherin and, through α-catenin, to the actin 
microfilament network of the cytoskeleton, connecting cell-cell adhesion with the intracellular 
mechanism  involved in cell shape and migration regulation. Due to the functional link between E-
cadherin complexes and cytoskeletal components, a change in the E-cadherin mediated 
adhesiveness leads to rearrangement of the cytoskeleton and, and at the same time, factors that 
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interfere with the latter will also affect the former. The binding of E-cadherin with catenins and 
actin cytoskeleton is essential for the formation of strong cell-cell adhesion and any event that 
perturbs the cadherin/catenin/cytoskeleton complex leads to destabilisation of cell-cell adhesion and 
reorganization of the actin cytoskeleton. E-cadherin based junctional complexes keep epithelial 
cells in a stationary, non-motile state and, therefore, disruption of cell-cell adhesion is of major 
importance in tumor invasion. E-cadherin acts as a tumor suppressor against invasion and 
metastasis, and its function is abolished during the malignant progression of most carcinomas by a 
variety of mechanisms. In this regard, it is noteworthy that one of the main changes occurring in 
both normal embryonic and pathological EMTs is the down-regulation of E-cadherin that leads to 
disorganization of the epithelial architecture and allows dissociation of single cells from their 
neighbours. A complete list of  markers for detecting EMT is shown in Table 3. 
 
Table 3. Epithelial-Mesenchymal Transition markers 
Potential marker Characteristics Cellular localization 
Mesenchymal markers; up-
regulated during EMT 
  
FSP1/S100A4 Fibroblast calcium-binding protein Nucleus and/or cytoplasm 
Vimentin Mesenchymal intermediate 
filament 
Mainly cytoplasm 
SLUG (SNAI2) Snail homolog 2 (Drosophila); 
zinc finger transcriptional 
repressor 
Nucleus 
Twist Up-regulated in mesenchymal Nucleus 
Epithelial markers; down-
regulated during EMT 
 
 
E-cadherin Type-1 transmembrane 
glycoprotein in adherent junctions 
Membrane 
Cytokeratin Intermediate filament keratins 
found in the intracytoplasmic 
cytoskeleton 
cytoplasm 
Others   
Beta-catenin Subunit of the cadherin protein 
complex. Armadillo family of 
proteins. 
Normal epithelium: membrane. 
Mesenchymal cells after EMT 
mainly nuclear:  
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Another major protein involved in the change of the epithelial phenotype is the fibroblast-specific 
protein Fsp-1, also called S100A4; this protein is extensively linked to the mesenchymal phenotype 
and is considered as a marker of EMT. It is a cytoplasmic protein interacting with the cytoskeleton 
which seems to associate with mesenchymal-type cell morphology and to contribute strongly in 
motile events.  
S100A4 is also expressed in metastatic carcinoma cells indicating that the mechanism underlying 
metastatic progression could involve EMT. 
Wnt, TGF-β, hedgehog, Notch and nuclear factor-Κb signaling pathway have been found to be 
critical for EMT induction. In vivo, a reversion from mesenchymal cancer cells to more 
differentiated ephitelial cells, the reverse process called mesenchymal-epithelial transition (MET), 
has been shown in metastatic sites of human colonrectal adenocarcinomas, suggesting that the 
dedifferentiated mesenchymal phenotype is dynamic and reversible, as shown in Fig.ure 8 [24].  
E-cadherin is regarded as a ‘master’ regulator of the epithelial/mesenchymal phenotype switch, as 
its repression can be sufficient to both induce and complete EMT and, on the other hand, its re-
activation can result in MET.  
 
 
1.7 Small animal imaging: an important tool in the pre-clinical research. 
The use of animal models in preclinical and basic studies makes possible to test diagnostic markers 
and drugs offering data that are more predictive of the distribution and efficacy of a compound. In 
recent years, new technologies have become available for imaging small animals. Noninvasive 
imaging in small living animal models has increasing importance in preclinical research becoming 
an independent speciality today [25]. Six are the most important imaging systems used for imaging 
small animals today. In succession, descriptions of these systems and their mail characteristics are 
reviewed below.  
 
1.7.1  Imaging optico 
Different devices are commercially available today because progress in the field of optics has 
revived interest in optical imaging as a powerful preclinical application. 
Biomedical optical imaging includes bioluminescence and fluorescence imaging. Bioluminescence 
consists in the enzymatic generation of visible light by a living organism; it’s a naturally occurring 
phenomenon in many non-mammalian species. Luciferases are enzymes that catalyze the oxidation 
of a substrate to release photons of light; the firefly Luciferase gene (luc) and the Renilla Luciferase 
gene (ruc) are the mainly used. In vivo bioluminescent imaging (BLI) needs genetic-engineered 
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cells containing an expression cassette in which bioluminescent report gene is constitutively 
expressed under the control of a selected gene promoter [25]. Mammalian  tissue do not emit light 
naturally, so BLI is esteemed to be believable because imaging are generated with very little 
background and there is not autofluorescence to disturb the signal (Fig. 10). Moreover, because 
bioluminescence does not need stimulation of external light source, the problem of the excitation 
beam penetrating the tissue does not exist. 
       
     
 
1.7.2 Micro-RM 
It’s a powerful tool for imaging study in small animals. Thanks to micro-Magnetic Resonance 
(micro-MR), with a resolution of 10-100 µm, it’s possible to obtain both anatomical and metabolic 
images; it’s performed using horizontal-bore devices with static field ranging from 4.7 to 9.4 Tesla 
putting anesthetized animal on 20 to 40 cm tray [26]. Liquid cooling systems are used to obtain low 
temperature required for superconductivity for high-field magnets based on cryomagnets. T1 and 
T2 relaxation times are dependent on the magnetic field. To date, hybrid systems are being 
developed, such as MRI/PET, in order to increase complete information from a single device. 
 
1.7.3 Micro-CT 
Micro-Computed Tomography (Micro-CT) is the miniaturization of CT, a technique commonly 
used in clinical diagnostic imaging. It’s able to supply very high resolution anatomical images, up 
to 9 µm, with three-dimensional views [25]. The use of specific contrast agents can further improve 
examination of soft tissue allowing studies of heart, angiogenesis and tumor growth; moreover, this 
technique is actually useful for studying pulmonary diseases, such as asthma and chronic 
obstructive pulmonary diseases. Most systems use a cone-beam X-ray source together with a solid-
state detector that rotates around  animals; in this way it’s possible imaging the entire animal in a 
single scan. Second-generation micro-CT systems are based on the technology used in clinical 
Figure 10. Example measurement Region of Interest (ROI, red cycle) 
for planar spectral analysis. Pseudo-color image overlaid on a gray-
scale photograph. 
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practice, including for example arrays with smaller detector elements and more powerful X-ray 
tubes, which allow faster scan (0.8 sec for the entire animal) and the possibility of performing 
perfusion studies, as well as the use of contrast agents. In fact, the use of iodinated contrast agents  
has improved image contrast so that it is possible to visualize 20 µm small-diameter vessels. Micro-
CT  systems have traditionally been used to study bone taking advantage of the favorable contrast 
between bone and soft tissue. It’s really useful for studying soft-tissue and in characteristic 
anatomical phenotypes in transgenic animals [27]. 
 
1.7.4 Micro-PET 
Positron Emission Tomography (PET) produces images of a biochemical function or process of the 
body on the bases of the activity of a positron-emitting radiotracer. The use of this technology is in 
expansion, although it is limited by the availability of a cyclotron and a radiopharmacy for the 
synthesis of the radiopharmaceuticals, determinant factors for the successful use of the technique. 
Fluorodeoxyglucose (FDG) labeled with the isotope 18F is the most commonly used. Micro-PET is 
specific, due to the possibility to mark a given molecule with a radioisotope without disturbing its 
biological function; it’s  sensitive, between 10 and 100 time greater than CT and MR; it can 
quantify the tissue concentration of the tracer. On the other hand, this technique lacks of anatomical 
information and the radioactive compounds are characterized by a very short half-life. Micro-PET is 
useful to provide a variety of metabolic data, such as functional and oncological imaging with FDG, 
studies of novel radiopharmaceutical or ligand receptors and, in recent years, it finds its utility in the 
study of the gene expression. 
 
1.7.5 Micro-SPECT 
Single photon emission computed tomography (SPECT, or less commonly, SPET) is a nuclear 
medicine tomographic imaging technique using gamma rays. In contrast with micro-PET, this 
system uses radioisotopes (xenon-133, iodine-123, for example) with long half-life, which don’t 
needs a cyclotron to be produced [25].  Moreover, these radioisotopes are more available that those 
used in PET. In clinical practice, system used for studying large regions of the patient have a 
collimator with parallel holes not able to do enlargements. On the contrary, this technique applied 
for imaging small-animal requires must higher spatial resolution for imaging small objects. So, 
collimators capable to produce spatial resolution <1 mm are necessary. Limitation of Micro-SPECT 
are linked to the signal loss due to the collimator-induced attenuation of many incident photons and 
the decline of the photons signal when they go through the tissue ; moreover, in order to produce an 
adequate signal for image formation, elevated activity of the radiopharmaceutical is needed.  
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This technique can be used to monitor physiological function, metabolic processes, specially in 
brain activity, and quantify receptors density. 
 
1.7.6 Micro-US 
Micro- Ultrasound (Micro-US) is based on the use of sound waves specially for imaging soft tissue, 
it’s relatively inexpensive but it’s limited by the tissue depth or artifacts caused by bone or air 
between soft tissue. Even if faster and less referral than all the other technique described on top, is 
not as widespread as other imaging modalities, with the exception of the study of accessible 
biological structures such as the urinary bladder and blood vessels [28]. This technique can be used 
to a faster monitoring of tumor growth, just in order to see the presence of the masses. 
 
 
1.8  In vivo Bioluminescence Imaging (BLI) 
BLI is a no-radioactive imaging modality, in contrast o the other modalities such as PET, SPECT or 
CT, described before. On the other hand, BLI is not an absolutely quantitative imaging approach 
like PET or SPECT. This technique allows longitudinal monitoring of tumor growth, spread, and 
response to treatment in preclinical cancer models within the same individual, with no requirement 
to euthanize. This is of significant benefit as each animal comprises its own control; therefore fewer 
animals are needed per study, which reduces overall costs and labor. 
Bioluminescence regards the enzymatic generation of visible light by living organism, a capacity 
typical of many lower organism including species of bacteria, marine creatures and insects such as 
firefly beetle. In nature, Luciferase genes encode proteins that act on substrates including D-
Luciferin, the most commonly used in animal tumor models, or the coelenterazine for Renilla 
Luciferase (ruc). The choice of the reporter is dependent on the goals of the research, but 
coelenterazine substrate is less stable than the other one so that this kind of biochemical obstacles 
limit its use in research. 
The firefly Luciferase (luc) is a molecule of 61 kDa, while Renilla Luciferase is smaller (36 kDa). 
Firefly Luciferase needs the presence of ATP, oxygen and magnesium in order to work, whereas no 
cofactors are required by Renilla Luciferase (Fig. 11). Light emission from the firefly Luciferase-
catalyzed Luciferin reaction is broad-band (530–640 nm), peaks at 562 nm and its signal is stronger 
and persists more than ruc; Renilla Luciferase emits blue light al 482 nm, less quantity is necessary 
in comparison with the other one, but it’s not efficient as Luciferin, even if no cofactors are required 
for the reaction. Since separate signal are distinguishable, it is possible to use both Luciferase in the 
same animal [29].  
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Figure 11.  Bioluminescence reporter cassette and Firefly Luciferase-Luciferin reaction 
 
The light emitted by Luciferase penetrates tissue depths of several millimeters to centimeters, 
however photons intensity decreases 10-fold for each centimeter of tissue depth. Sensitive light-
detecting instruments must be used to detect bioluminescence in vivo in order to measure the 
number of photons emitted per unit area. Several commercially available systems are capable of 
detecting low levels of light. In general, these systems include a light-tight imaging chamber into 
with the animal is placed. Above this chamber sits a sensitive a charge-coupled device camera 
(CCD) that  detect bioluminescence and converts photon flux detected into electrons. The CCD 
camera is cooled to -90° C in order to reduce thermal noise. In this way, the ability to detect low 
level of light is increased [30]. The data is measured in photons but the pseudo-color graphic allows 
rapid visual interpretation. Scientific image data is a two-dimensional array of numbers. Each 
element of the array or pixel contains a number that is proportional to the light intensity on that 
element. The CCD camera used for scientific imaging is essentially an array of photosensitive 
pixels and each pixel collects photons during an image exposure. 
A subsequent electronic readout provides a photon intensity number associated with each pixel. In a 
bright area of the image, more photons are detected and the photon intensity number is greater than 
that in a dimmer area of the image. Images acquisition is typically ranging between 1 e 180 sec and 
is controlled by software for final image analysis. It’s really useful to have the Luciferase image 
superimposed with other type of image, provided in Magnetic Resonance for example, in order to 
anatomically allocate the emission signal.   
In vivo studies assessing tumor burden relative to bioluminescent signal have shown strong 
correlations between viable cells and bioluminescence. Dead or necrotic regions within a tumor, 
potentially indicative of a positive drug response, contribute to volume; therefore the ability to 
solely measure viable cells soon after treatment is advantageous for rapidly assessing drug efficacy 
over traditional volumetric-based measurements. BLI may therefore be useful in ‘prevention trials’ 
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for drugs specifically targeting the early stages of tumor development. As the whole animal is 
imaged, unpredictable sites of metastasis are evident and can be rapidly identified. Firstly, the 
efficiency of bioluminescent light transmission through an animal from its origin depends largely 
on the type and depth of overlying tissue as well as its scattering properties. 
Haemoglobin absorbs light; therefore highly vascularized organs tend to have lower levels of light 
transmission compared with skin or muscle. Secondly, BLI traditionally has provided two-
dimensional (2D) planar images with limited spatial and depth resolution. Recent advances have 
enabled the translation of BLI data into 3D tomographic imaging, thereby theoretically providing 
better quantification and signal localization.  
 
 
Figure 12. 3D tools in the 3D view window 
 
BLI does not provide anatomical information, software has been developed in order to superimpose 
virtual murine organs within a 3D bioluminescent image, a sort of “mouse atlas” that can help to 
predict the internal origin of bioluminescent signal when used in combination with 3D BLI 
protocols. Signal depth can be estimated by measuring the ratio of red to green emitted light on the 
surface of the animal from multiple aspects and computing its likely origin. Hypoxic regions within 
tumors may also affect signal intensity [31]. Bioluminescence is dependent on oxygen and a 
number of studies have found that the amount of light emitted from Luciferase- labeled cells is 
reduced as the oxygen concentration decreases. Oxygen tension limits for BLI are still not fully 
defined, however, and the HIF-1 (hypoxiainducible factor 1) promoter has been successfully used to 
express Luciferase and to report hypoxia in vivo. Similar to PET, the spatial resolution of BLI is 
relatively low (1–2 mm), due to the scattering and diffraction of light through tissue [32]. This can 
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make the precise localization of the signal source difficult to ascertain and a detailed assessment of 
primary tumor anatomy is often limited. Comparisons between different animal subjects may also 
be complicated by the variable depth of tumors in each, as the light signal will be variably 
attenuated. Although this problem may be overcome by using each animal as its own control, it is 
important to ensure that the animal is accurately and reproducibly positioned each time an image is 
acquired. Table 4 summarizes BLI applications in pre-clinical research.  
 
Table 4.  BLI in pre-clinical research. 
Application Example 
Animal models Xenograft, orthotopic, and GEM models of human 
cancer have been developed which express 
luciferase 
Drug development BLI allows therapeutic efficacy of cancer drugs to 
be established 
Monitoring of genes 
 
Luciferase-labelled cells may be used to monitor 
gene delivery and gene expression in vivo 
Genetic screening has also been performed using 
BLI, allowing identification of specific oncogenes 
Tumor development 
 
BLI may be used to study processes such as 
angiogenesis, apoptosis, and adhesion in cancer 
cells 
Metastasis High sensitivity of BLI allows the imaging of 
metastasis and minimal residual disease states in 
cancer models 
Protein interactions BLI has been used to image protein–protein 
interactions in vivo 
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II. AIMS OF THE STUDY AND DESIGN OF THE PROJECT 
 
Pancreatic cancer remains one of the most lethal malignancies. Despite the efforts made in the past 
50 years, conventional treatment approaches have little impact on the course of this aggressive 
neoplasm and the final resolution doesn’t seems imminent yet. Moreover, to date an effective system 
is also still strongly needed, which accurately predict the clinical efficacy of new compounds 
developed in oncology for pancreatic cancer treatment.  
The aim of the current study is to contribute to the generation of a complete and straightforward 
system useful for the identification of novel drug for pancreatic cancer treatment. This system 
should provide the techniques, the protocols and a pancreatic cancer model suitable for in vitro 
high-throughput compounds screening first and in vivo validation of the selected molecules then. 
It has become increasingly clear that many tumors contain a very small subpopulation of cancer 
stem-like cells (CSCs) which are hypothesized to be the more aggressively growing and the more 
chemoresistant cell population of a tumour. For these reasons a well established CSCs cell line is 
considered the most interesting cancer model on which novel therapies can be in vitro and in vivo 
tested. CSCs, finally, offer the opportunities to develop therapies which actually enhance survival 
rate and life quality  
The first goal of the current study was to complete the characterization of spheres growing pancreatic 
CSCs (Panc1-spheres),previously obtained in our lab from Panc-1 adherent cell line. We are going 
to use Panc1-spheres as pancreatic cancer model in our generating compounds screening system. 
To in vivo confirming the aggressiveness, in term of growth rate and invasion capacity, already 
demonstrated by sphere growing cells in in vitro assays, we performed subcutaneous and 
orthotopical injections in nude mice with Panc1 and Panc1-sph cells. Tumor growths were followed 
using MRI. In order to underline the most malignant phenotype of Panc1-sph vs adherent Panc1 we 
also studied EMT on tumors derived from this experiment and on cytospinned cells. 
Moreover, looking to troubles we encountered during Magnetic Resonance Imaging (MRI) 
acquisitions, we observed that an improvement of imaging strategies was actually needed, in order 
to better control above all the formation of small masses as metastasis and early primary tumors. 
Mirroring the importance of these mouse models in the pre-clinical testing, we decided to focus our 
attention to the most important non-invasive small animal-imaging modalities available today, in 
particular MRI, Micro-Ultrasound (US) and In Vivo Bioluminescence Imaging, tracing 
disadvantages and advantages of each one.  
Then, the second goal was to correlate these techniques and  arrive to the point to have an “imaging 
protocol”, able to offset some of the limitation  of each modality when used alone, to be used in our 
generating compounds screening system.  
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III. Materials & Methods 
 
3.1 Cells lines and culture conditions  
Human pancreatic cancer cell lines Panc-1 were grown in RPMI (Cambrex Bioscience, Milan, 
Italy) supplemented with 10% fetal bovine serum (FBS, Cambrex Bioscience, Milan, Italy), 100 U 
ml-1 penicillin and 0,1 mg ml-1 streptomycin. Adherent cells were maintained in standard 
conditions for a few passages at 37°C with 5% of CO2 and detached using Trypsin-EDTA solution 
(trypsin, 0,25%, EDTA 0,02%). 
To generate suspension cells, and separate stem-like cells, adherent cells were washed twice in D-
PBS 1X (Cambrex Bioscience, Milan, Italy) and then cultured in DMEM+F-12 (1:1) +1X B27+ 
250 mg/ml Fungizone+ 1% penicillin/ streptomycin (Gibco, Invitrogen) + 5 mg/ml Heparin (Sigma, 
Inc), supplemented with 20 ng/ml EGF and FGF (Peprotech, Inc). The medium was further referred 
to as ‘Cancer Stem Cell medium’ (CSM). Adherent cells were left in CSM for at least 3-4 weeks or 
until the appearance of floating cell aggregates, further referred to as pancreatic cancer spheres. 
Spheres were then collected without disturbing the adherent cells and sub-cultured in CSM for at 
least four passages before initiating the in vitro and in vivo characterization experiments. 
Human pancreatic cancer cell lines Panc-1 Luc+ were kindly provided by Dr. Scott Kern 
(Departments of Surgery, Pathology, and Oncology, The Johns Hopkins Medical Institutions, 
Baltimore, Maryland, USA) and maintained under G418 selection. We tested the bioluminescence 
activity of Panc-1-Luc+ cells before their injection in vivo in our mouse model such as their 
capability to grow in an in vivo system inoculating them in the flank of 5 mice. 
 
3.2 Subcutaneous Pancreatic Cancer Xenografts 
All animal experiments have been carried according to the ethical standards of the Verona 
University Review Board, and the animals were maintained in accordance with the institutional 
guidelines. 
At first, 2x106 adherent and sphere-growing pancreatic cancer cells in a final volume of 100 µl were 
injected into the right flank of female athymic CD1 mice (4 weeks old, Charles River). 
Animals were monitored for tumor growth for an overall period of 30 days.  
Tumor volumes and body weight were recorded twice weekly for the complete period. 
Tumor volumes were calculated using the formula 
V=(a * b2)/2 
Where where a is the biggest and b the smallest orthogonal tumor diameter. 
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3.3 Generation of orthotopic human pancreatic xenografts in immunodeficient mice.  
All animal experiments have been carried according to the ethical standards of the Verona 
University Review Board, and the animals were maintained in accordance with the institutional 
guidelines. 
At first, 5*105 adherent and 5*105 spheres cells in a volume of 30 µl of PBS were injected into the 
pancreas of female athymic CD1 mice (4 weeks old, Charles River). We divided the animals into 
two groups: five of them received 500.000 spheres cells, the other one received 500.000 adherent 
cells. For all successive experiments, the amount of 5*106 (Gruoup one) and 2*106  (Group two) 
adherent Panc1-Luc cells in a total of 60 µl of PBS containing 1% serum-free Matrigel (vol/vol) has 
been applied. The syringes containing the cells suspension were put into ice during all the time of 
surgery. 
Animals were anesthetized using Ketamine/xylazine cocktail at a ratio of 100 mg kg -1 : 20 mg kg -1 
placing the mice under a heat lamp. Once anesthetized, the mouse was placed on its right side 
painting the left side from the base of the neck to the tail with 70% (vol/vol) ethanol. The 
abdominal skin was picked up with forceps and a 1-cm incision with sterile micro-scissors was 
made slightly medial to the splenic silhouette. A second 1-cm incision was extended on the 
abdominal cavity without injury to the underlying organs. Using a pair of blunt-nose forceps, gently 
the tip of the pancreatic tail was grasped and the pancreas/spleen externalized in the lateral 
direction, exposing the entire pancreatic body and spleen. While gently retracting the pancreas 
laterally, we inserted the needle into the tail of the pancreas and passed in the pancreatic head 
region; slowly the cells solution was injected while withdrawing the needle to the mid-body of the 
pancreas forming a fluid-filled region within the pancreas parenchyma. When Matrigel was used, 
the pancreas was left externalized and untouched for 2 minutes waiting for the Matrigel 
solidification. 
Then, the pancreas/spleen were internalized with blunt forceps and the abdominal muscle layer 
closed with continuous 4-0 suture, while the overlying skin was closed with a second set of 
interrupted 3-0 silk suture. The negative control group was constituted by five mice which received 
only Matrigel (60 µl). 
All the mice were recovered from the effects of the anesthetic, continuing to monitor the 
temperature, skin color and respiratory rate under a heat lamp.  
Mice were recovered from the procedure once they were in the sterna position, responded to the 
external stimuli and freely moved about inside the cage. 
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3.4 Optical imaging 
We used VivoVision Systems, IVIS® 200 Series, Imaging System for small laboratory animals, 
Xenogen (Xenogen Corporation, Alameda USA), an advanced optical imaging system designed to 
improve quantitative outcomes of in vivo imaging. It’s constituted by a camera sensor back thinned, 
back illuminated grade CCD 1 (2.7 x 2.7cm, -90° C), with a minimal image pixel resolution of 
20µm (pixel dimension 13.5µm, imaging pixels 2048 x 2048), quantum efficiency >85%  between 
500 and 700nm, and > 30% between 400 and 900nm, and a 150W Quartz halogen 3250° Kelvin 
lamp. The stage of the instrument is heated to 37° C. IVIS 200 Series can work in two different 
modalities: fluorescence and bioluminescence modality. It is equipped with a set of excitation and 
emission filters: GFP (445-490nm), GFP background (410-440nm) DsRed (500-550nm), DsRed 
background (460-490nm) Cy5.5 (615-665nm), Cy5.5 background (580-610nm), ICG (710-760nm 
and ICG background (665-695nm). For bioluminescent spectral imaging applications, it have a 
specific filters set to characterize Luciferase-Luciferin system emission (560-580-600-620-640-660 
nm) and it has a laser scanner that provides 3D surface topography for single-view diffuse 
tomographic reconstructions of internal sources. 
Images were acquired and analyzed with Living Image 2.6 software and Living Image 3D 
(Xenogen Corporation, Alameda USA). The animals were placed in the Xenogen’s induction 
chamber and  anesthetized using 2.5-3.5% isofluorane. When the mice were in a moderately deep 
plane of aesthesia, breathing rhythmically, they were removed from the induction chamber and 
transferred in the imaging chamber putting their heads in the nose cone of the anesthesia manifold.  
The tube that supplies the anesthesia to the box is split so that the same concentration of anesthesia 
is plumbed to the anesthesia manifold located inside the imaging chamber. The animals can be 
manipulated while they are in the chamber as long as their heads remains in the nose cone. 
They were injected in the lower left abdominal quadrant with Luciferin (15 mg/mL or 30 mg/kg, in 
PBS, dose of 150 mg/kg, D-Luciferin, Firefly, potassium salt, 1.0 g/vial, Caliper Life Sciences) 
given intraperitoneally for firefly Luciferase.  
We Prepared a fresh stock solution of Luciferin at 15 mg/mL in DPBSfor each imaging session. 
The fresh solution was filter sterilized through a 0.2 um filter. 
We performed the acquisition protocol using these parameters: Total Time of acq. 300 seconds; 
Binning = 8; f/stop (diaphragm opening) =1 and 2; excitation filters =block; emission filters = open; 
photographic parameters: time=0.2seconds, binning = 4, f/stop=8; field of view = 12.8cm; high of 
sample =1.5cm. Two Region of Interest (ROI) were selected for each animal: one refers to total 
abdomen cavity, and one draws only around primary tumors sources emission. 
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3.5 Ultrasound 
All the Ultrasound (US) examinations were performed on a Technos (Esaote, Milan, Italy) with 
harmonic imaging setting at low acoustic ultrasound pressure (CnTI, 16 MHz; MI < 0.1; DP 15 
kPS).   
The mice were placed on a table in supine position. An axial scan of the abdomen was taken, in 
order to locate the spleen and the pancreas, as point of references for the localization of the 
implanted tumor.  
After the localization, three measures of each tumor were taken, in order to evaluate the 
approximately volume. 
 
3.6 Magnetic Resonance Imaging  
Mice were anesthetized by inhalation of a mixture of air and O2 containing 0.5–1% isofluorane and 
placed in prone position into a 3.5 cm i.d. transmitter-receiver birdcage coil. Images were acquired 
using a Biospec Tomograph (Bruker, Karlsruhe, Germany) equipped with a 4.7 T, 33-cm bore 
horizontal magnet (Oxford Ltd., Oxford, United Kingdom); respiration rate were monitored. All 
mice were put in a supine position and fixed with tape on all extremities and the tail. The imaging 
planes were coronal and trasverse. The MR sequence parameters used in this study are summarising 
in Table 5. 
 
Parameter 
Coronal T2 SE with  
fat-suppression 
(RARE) 
Trasverse T2 SE 
with fat-suppression 
(RARE) 
 
RARE T1 e T1 evo 
TR 5000 ms 5000 ms  
TE 1 67,2 ms 56 ms  
TE 2 67,2 ms 56 ms  
Average 2   
Field of view 5,30 cm 5 cm 3 cm 
Matrix size 256 x 256 256 x 128 256 x 128 
Repetition time 4398,6 ms   
Echos 1   
Interslice 1 mm 1 mm 0,75 mm 
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Slices 15 20 12 and 22 respectively 
Slice thickness 1 mm 1 mm  0,75 mm 
 
After T2-weighted images were acquired, for the last imaging session before sacrifice, all animals 
received Gadolinium (Gd)-DTPA (10 µl/10gr), 1:5, BW, Magnevist TM, Schering, Berlin, 
Germany), injected in the vein of the tail 15 min prior to imaging to enhance the contrast of the 
pancreas to the surrounding tissue in order to better delineate the tumor. 
 
3.7 Cytospin  
We used 4*105 cells washed in cold PBS twice and diluted in 500 µl of cold PBS.  All samples were 
put on ice. 
Slides and filters were placed into appropriate slots in the cytospin with the cardboard filters facing 
the center of the cytospin; quickly 500 µl of each sample were aliquoted into the appropriate wells 
of the cytospin and spinned at maximum speed for 5 minutes. 
 
3.8 Histological and Immunohistochemical analysis of tumor xenografts 
Necropsies were performed by cervical dislocation of anaesthetized animals. Tumor samples were 
formalin-fixed, embedded in paraffin, sectioned and deparaffinized using xylene, and hydrated by 
series of decreasing ethanol washes. Hematoxylin/Eosin was performed for each samples.  Ki-67 
(clone, MM1 Novocastra), p53 (Novocastra), CK7 (Biogenex), E-Cadherin (Dako), S100A4 
(Rabbit mAb, Dako) and Slug (C19G7, Rabbit mAb, Cell Signaling) were  diluted respectively 
1:50, 1:20, 1:500, 1:20, 1:500 and 1:50;  antigen retrievals were performed at 95° for 15 min in 
buffer citrate pH=6. Vimentin (Biogenex) was diluted 1:500; CXCR4 (Abcam, rabbit mAb) was 
diluted 1:100 and antigen retrieval was performed at 95° for 15 min in buffer citrate pH=6, while 
Twist (Santa Cruz) was diluted 1:80 and antigen retrieval was performed at 95° for 15 min in buffer 
citrate pH=8. 
Histology was performed with H&E staining. 
All slides were acquired using Aperio Scan-Scope  XT system.  
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IV. RESULTS 
 
4.1  Panc-1 spheres show higher proliferation rate than adherent cells in vivo: 
subcutaneous mouse model 
To assess the tumorigenicity properties of Panc-1 adherent cells and spheres, cells were 
subcutaneously injected in nude mice. 
In this experiment,  2*106 Panc-1 adherent or Panc-1 sphere growing cells were injected in the 
flanks of nude  mice. The tumor growth was monitored for 30 days twice a week with a caliper. 
Tumor volume was calculated as reported in section 3.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Representative images of the Ki-67 staining of Panc-1 spheres (A) and Panc-1 adherent 
cells (B). Images were acquired at 20X. The inserts are 40X. 
 
The proliferation index of both adherent cell and sphere-derived tumors was determined by Ki67 
immunostaining on paraffin-embedded tumor sections. As depicted in Figure 13, sphere-derived 
tumors demonstrate a significantly higher proliferation rate (70-80% positivity) when compared to 
adherent cell-derived tumors (40% positivity) (Fig.13). 
A 
B 
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4.2 Morphological analysis of the Panc-1 spheres vs adherent cells in the 
Subcutaneous Pancreatic Cancer Xenografts. 
The morphology of tumors derived from Panc-1 spheres and adherent cells were investigated in a  
xenograft mice model. Therefore, 2x106 cells of each cell type were injected subcutaneously in 
athymic female mice. 
After 35 days, mice were sacrificed; tumors were resected from skin, and processed using formalin-
embedded paraffin technology. H&E staining  (Fig. 14) demonstrated that sphere growing tumors 
established in nude mice showed more irregular mitotic figures than adherent cell-derived tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  H&E staining: comparison at different magnifications in tumors generated from Panc-
1 adherent at A) 20X, C) 40X, E)63X, and from Panc-1 spheres at B) 20X, D) 40X, and F) 60X. 
 
Moreover, adherent cells demonstrated a more organized architecture whereas the spheres generated 
a more dysplastic tumor structure. Spheres were less organized; they contained more apoptotic 
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bodies and more mitotic figures (Fig. 15 B) and had a higher stromal reaction, (Fig. 15 B, arrows). 
They also demonstrated cancer cell infiltration in the perineural tissue (Fig. 15 C, D, arrows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Stromal reaction of tumors generated from Panc-1 spheres A) 200X and B) 400X. 
Sphere-derived tumors infiltrated in perineural tissue C) 200X and D) 400X. 
 
 
4.3  Panc-1 spheres grow faster and are more aggressive than adherent cells in 
vivo: the orthotopic mouse model. 
In order to assess growth rate and aggressiveness of Panc-1-growing spheres respect to adherent 
Panc-1 cells,  we performed orthotopic injections with both kind of cells using nude mice. We 
repeated this experiment twice  (see section 2.3). In both cases, we divided the animals into two 
groups: five of them received  5*105 spheres growing cells and the other one received 5*105 
adherent cells, both suspended in 30 µl PBS.  
We followed tumor growth in MRI, setting the first control one month after surgery.   
All tumors grew both in the first than in the second experiment. We observed that mice injected 
with Panc-1 spheres growing cells developed tumor faster than mice injected with Panc-1 adherent 
cells: in mice receiving Panc-1 spheres growing cells , small masses were detectable in MRI 6 week 
after surgery (Fig. 16), whereas no tumors were seen at the same time-point in mice receiving 
adherent cells . The latter needed  other 2 weeks to develop detectable tumors (Fig. 17). 
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Figure 16.  MRI  T2-weight sequences (1 to 6)  of a mouse orthotopically  injected  with  spheres 
growing  Panc-1 cells, 6 weeks after surgery.  Animal is lying face down. A tumor mass are 
detectable. The red ring indicates the anatomical area in with tumor should  be grow (In picture 5: 
K= left kidney; S= Spleen; ST= stomach). Arrows indicates the developed tumor mass. 
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Figure 17.  MRI  T2-weight sequences (1 to 6) of a mouse orthotopically  injected  with  adherent 
Panc-1, 6 weeks after surgery.  Animal is lying face down. No tumor masses are detectable. The red 
ring indicates the anatomical area in which tumor should grow. (In picture 5: K= left kidney; S= 
Spleen; ST= stomach). 
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We observed tumor infiltration in the spleen, a phenomena already know in literature as “infiltration 
ad continuum” (Fig. 18) in one mouse injected with adherent cells and in two injected with spheres. 
Moreover,  in 4/5 mice  injected  with spheres, putative metastasis were detected during necropsy 
(Fig. 19), in the liver, stomach and intestine. No metastasis were found in mice injected with 
adherent Panc-1 cells. 
 
 
Figure 18. First orthotopic experiment: tumor infiltration in the spleen, “infiltration ad 
continuum”(red ring) , derived from spheres growing 
 
 
 
Figure 19. First orthotopic experiment: putative metastasis (black arrows), derived from spheres 
growing cells.  
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In the second experiment, as already seen in the first one, mice inoculated with spheres developed 
tumors faster that those inoculated with adherent cells (data not show).  
Putative metastasis were found in 5/5  animals injected with spheres, in which we identified the 
presence of small masses in the gut and tumor spots on the liver, as shown in the Fig. 20 and  21. 
One mouse injected with adherent cells showed metastasis in the intestine (data not shown). 
 
                     
Figure 20. Second orthotopic experiment: arrows indicate putative metastasis in the liver (picture 
on the left) and tumor mass attached to the spleen ( picture on the right). 
                        
 
 
           
 
Figure 21. Second orthotopic experiment: arrows indicate  small putative tumor masses  found in 
the intestine, from primary tumor derived spheres growing cells (picture on the left);H&E staining 
of the small tumor masses collected from the small intestine (picture on the right). 
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It have to be underlined that supplementary small masses attached to the small intestine were never  
identified during MRI analysis. The images below refer to the mouse shown in Fig. 19. It’s a MRI 
T2-weight sequence performed one week before necropsy; the primary tumor mass is clearly 
detectable (spotlight in green perimeter, Fig. 22). Images are clear and no breath artifacts are 
present. Even if all the conditions are favorable, no masses within the small intestine were found 
during MRI session, on contrary to what necropsy disclosed. 
 
 
 
 
 
 
 
 
ST ST 
ST 
ST 
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Figure 22.  MRI  T2-weight sequences (see slice from 1 to 20) of a mouse orthotopically  injected  
with  spheres growing Panc-1 cells, 1week before necropsy.  Animal is in supine position,  so the 
tumor mass is detected on the left of the image. No putative metastasis or minor tumor masses can 
be seen in other anatomical compartment, contrary to what we found at the end of the experiments 
during necropsy. (K= left kidney; ST= stomach).Green rings dyeline the primary tumor.  
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4.4 Morphological analysis of the Panc-1 spheres vs adherent cells in the 
orthotopic mouse model. 
The morphology of tumors derived from Panc-1 spheres and adherent cells was investigated in all  
orthotopic  tumor masses obtained after necropsies from both the two experiments (see section 4.3). 
Therefore, 5*105 cells of each cell type were injected in the pancreas of athymic female mice. 
After more or less 3 month from surgery, before first signals of suffering appeared because of the 
big size of tumors,  mice were sacrificed; tumors were processed  using formalin-embedded paraffin 
technology.  
Tumor derived from adherent cells showed different areas of organization, probably due to the 
eterogeneity of the starting population (Fig. 23). Instead, tumors derived from spheres growing cells 
were more homogeneous (Fig. 24) and  have dense tissue organization, because of their derivation 
from a selected subset of cells starting from adherent the Panc-1 cell line. H&E staining  
demonstrated that sphere growing tumors established in nude mice showed more irregular mitotic 
than adherent cell-derived tumors. 
         
 
a b 
Figure 23.  H&E staining of tumour derived 
from adherent cells. (a) Section of the 
tumour, acquisition at Aperio  0,3X; (b) 
acquisition at Aperio 1X; (c) acquisition at 
Aperio 10X. 
c 
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Figure 24. H&E staining of orthotopic tumors derived from spheres growing cells.  (a) Section of 
the tumor, acquisition at Aperio  0,3 X; (b)  acquisition  at Aperio 1 X, residues of normal pancreas 
on the left; (c) acquisition at Aperio 10 X, arrows indicate evident mitotic cells. 
 
 
 
a b 
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4.5 Epithelial-mesenchymal transition (EMT) in adherent Panc-1 and spheres 
growing cells Panc-1 cell lines.  
The epithelial-mesenchymal transition (EMT) is an orchestrated series of events in which cell-cell 
and cell-extracellular matrix (ECM) interactions are altered, the cytoskeleton is reorganized to 
confer the ability to move, and a new transcriptional program, typically resembling mesenchymal 
phenotype is induced. Even if it’s essential for embryonic development, EMT during tumor 
progression allows noninvasive and non metastatic tumor cells to acquire the capacity to infiltrate in 
the surrounding tissue and to ultimately metastasize to distant sites. We examined the expression of 
the most important EMT markers such as E-Cadherin, Vimentin, S100A4, Twist and Slug, in 
cytospinned adherent Panc-1 and spheres growing Panc-1, then in subcutaneous tumors derived 
from both cell lines and, finally, in tumors derived from each kind of cells orthotopically injected 
into the pancreas of nude mice. 
 4.5.1 EMT in cytospinnd adherent and spheres growing Panc-1 cell lines 
We performed immunohistochemical assay on adherent Panc-1cells culture and spheres growing 
Panc-1 cells in order to analyze the expression of EMT markers before they grow in vivo 
(subcutaneous and orthotopic sites). the two cell lines shows a little difference in term of E-
Cadherin expression, slightly more weak in spheres cells respect to adherent cells. Both adherent 
and spheres Panc-1 cells resulted strongly positive for the expression of Vimentin marker. We 
found an important different in the expression of S100A4 both in adherent and spheres cells: it was 
strong in spheres, and absent in adherent cells (Fig. 25). No considerable differences in the 
expression of Slug were found comparing the two cell lines, which results weakly positive in the 
cytoplasm of cells in few tumor areas. By nature, Twist was absent in adherent and spheres cells, 
even if the latter showed some atypical granule cells positive to Twist antibody (Fig. 26). 
 4.5.2 EMT in adherent and spheres growing Panc-1 from Subcutaneous Pancreatic 
Cancer Xenograft 
Tumors grown in subcutaneous xenografts showed very faint expression of E-Cadherin both in 
tumors derived from adherent than tumors derived from spheres cells; no important differences 
were found in Vimentin expression  such as Twist expression markers.  S100A4 probably displayed 
a slightly stronger expression in spheres derived tumors (Fig. 27). A strong difference of expression 
was found for Slug marker, resulting in a negative pattern for adherent derived tumors and a evident 
positivity in tumors derived from spheres, especially in tumor border (Fig. 28). 
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Figure 25. EMT markers expression in cytospinned Panc-1 adherent cells (left column)  and 
spheres-growing Panc-1 cell (right column). Acquisition at Aperio 10 X (couples 1-3) and 20 X 
(couples 2-4-5).  
 
 
 
 
Figure 26. Detail of Twist expression in spheres cells. Arrows show granules inside nucleus and 
cytoplasm.  
 
 
Adherent Panc-1 Spheres- growing Panc-1 IN VITRO 
5. Slug expression  
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Figure 27. EMT  markers expression in subcutaneous tumors derived from Panc-1 adherent cells 
(left column)  and tumors derived from spheres-growing Panc-1 cell (right column; it’s a detail of 
Fig.ure 27). All acquisition were performed at Aperio 20 X.  
 
 
 
 
Figure 28. Expression of Slug in a section of subcutaneous tumor derived from adherent Panc-1 
determinate by immunohistochemistry. Picture shows that  Slug localizes mainly in the tumor 
border.  
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 4.5.3 EMT in the Orthotopic Pancreatic Cancer model. 
We analyzed the expression of EMT markers in primary tumors derived adherent cells and spheres-
growing Panc-1 cells. All orthotopic tumor masses were characterized by a strong lymphocyte 
infiltration. 
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Figure 29. EMT markers expression in orthotopic primary tumors derived from Panc-1 adherent 
cells (left column)  and tumors derived from spheres-growing Panc-1 cell (right column). All 
acquisition were performed at Aperio 20 X. 
As shown in Fig. 29, differences in EMT markers expression in orthotopic primary tumors 
immunohistochemistry are more evident than  in the subcutaneous growing tumors derived from 
both cell lines. Except of  E-Cadherin expression, that displays starting low intensity in the 
adherent-derived Panc-1 tumors and completely disappears becoming negative in spheres-derived 
tumors, in all the other cases, the expression of Vimentin and S100A4 markers increase 
appreciably. In particular, similarly to how shown in Fig. 26 regarding the subcutaneous mouse 
model, an increase expression of Slug can clearly be appreciate; moreover, in the case of the 
orthotopic growth of tumor cells, we observed an increase expression of Twist in sphere-derived 
primary tumors if compared with what happens in adherent-derived primary tumors. Twist 
expression resulted positive in tumors derived from spheres, even if only in a  few cells,  in 
particular for those  closed to necrotic areas of the tumor mass.  
4.  Twist expression  
5.  Slug expression  
Adherent Panc-1 Spheres- growing Panc-1 
IN VIVO Orthotopic Pancreatic 
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 4.5.4 EMT in the Orthotopic Pancreatic Cancer model: analysis of putative metastasis  
As said before in section 4.3, putative metastasis were found in 9/10 animals injected with spheres, 
in which we identified the presence of small masses in the gut and tumor spots on the liver (as 
shown in the Fig. 19 and  Fig. 20).  
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Figure 30. EMT markers expression in putative metastasis derived from spheres-growing Panc-1 
cell. All acquisition were performed at Aperio 20 X. Arrows in section for Twist staining (point 4) 
reports an example of necrotic area, that appears strongly colored because of aspecific DAB 
accumulation. Points 5(b) and 5(c)  indicate differences in  Slug expression in the same section. 
 
Immunostaining for EMT markers shows that E-Cadherin was not expressed in secondary masses 
found in the intestine. Vimentin displays a strong positivity such as S100A4 especially localizing in 
the cytoplasm (more than 50% cells are positive), where the staining was more intense. Similarly to 
what happens in primary orthotopic tumor, from which these masses may derive, both Twist and 
Slug are expressed in an irregular way, both in nuclei and in cytoplasm, in a non homogeneous way, 
but closed to necrotic regions (with regard to Twist, in the pictures necrotic areas are strongly 
colored in brown because of the aspecific DAB accumulation; positive cells are detectable closed to 
these areas) or rather along tumor border, but not in the center of the tumor, in the case of Slug 
(Fig.30).    
 
 
5. Slug expression 
a 
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4.6  Staining for CK7 in adherent and spheres-derived orthotopic tumors  
We studied reactivity to cytokeratin 7 (CK7) in both adherent and spheres cells-derived orthotopic 
tumor. Cytokeratins are intermediate filament proteins present in epithelial cells. They are 
expressed in a tissue-specific manner in normal organs and the tumors that arise from them. 
Monoclonal antibodies have been established against several of the cytokeratin polypeptides and are 
used to evaluate the pattern of cytokeratin expression in cells of epithelial origin. CK7 is as marker 
that indicates the grade of differentiation of a tissue. In Panc-1 adherent-derived orthotopic tumors, 
CK7 expression  is characterized by patterns with variable degrees of cytoplasmatic staining (Fig. 
31). 
 
 
     
Figure 31. (a), Expression of CK7 in Panc-1 adherent-derived orthotopic tumor. Staining for CK7 
is more intense only in a part of the tumor, whereas the others are completely negative. CK7 
expression  is characterized by patterns with variable degrees of cytoplasmatic staining. 
Lymphocytes infiltration is strong (arrow). Acquisition at Aperio 20X (b) and 4X (c).   
Adherent-derived orthotopic tumor 
a 
b 
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The tumor mass is divided in a very clear way in areas in which staining of CK7 is positive, such as 
others one in which CK 7 expression is totally absent.  
Infiltrating CK7-negative tumors cells are clearly detectable within CK7-positive tumor areas, 
creating zones in which the contrast between positivity and negativity to CK7 staining is strong 
(Fig. 32). Necrosis delimitate these positive and negative areas among them.  Lymphoid component 
is strong (arrow in Fig.32,d). 
 
 
         
             
Figure 32. Details of negative CK7 tumor area in Panc-1 adherent-derived tumor and of a small 
negative CK7 area in a region in which the expression of CK7 is strong. 
 
Immunohistochemistry for CK7 for spheres-derived orthotopic tumors displays a more 
homogeneous sight than that in adherent-derived tumors. A part of necrotic regions in which 
aspecific DAB accumulation is strong, creating a non-specific reaction, these tumors showed no 
CK7 expression. The organization of the tumor masses appear regular if compared with the 
Adherent-derived orthotopic tumor 
a b 
c 
d 
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adherent-derived tumor; mitotic activity is stronger, as already shown previously, and also 
lymphoid invasion seems to be less important than in the adherent-derived tumor (Fig.33). 
 
            
 Figure 33.  Details of negative CK7 area in Panc-1 spheres-derived tumor. Red asterisks indicate 
residual pancreatic ducts within the tumor mass. Arrows show residual normal murine pancreas. 
 
4.7  Ki67 labeling index 
The proliferation index of both adherent cell and sphere-derived orthotopic tumors was determined 
by Ki67 immunostaining on paraffin-embedded tumor sections, as done for subcutaneous tumors. 
As depicted in Figure 34, sphere-derived tumors demonstrate a significantly higher proliferation 
rate (80% positivity) when compared to adherent cell-derived tumors (30% positivity) (Fig.34). 
 
   
 
Figure 34. Representative images of the Ki-67 staining of Tumor derived from Panc-1 adherent 
cells (A) and tumor from Panc-1 spheres cells (B). Images acquired at Aperio 40X.  
Spheres -derived orthotopic tumor 
** ** 
A B 
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4.8  In vivo imaging: advantages and limits of MRI 
As mentioned before in paragraph 4.3, tumors growth after orthotopic injections in mice was 
followed by MRI, starting from one month after surgery. This technique allowed to detect the 
primary tumors and to follow their growths during the time but it was not able to detect putative 
metastasis adhering to the surface of small intestine or to the liver, even if they were founded during 
necropsy (for a total of 9/10 mice injected with spheres growing cell).  Actually, pancreas imaging 
in mice is particularly difficult because this organ is not a solid retroperitoneal organ like in humans 
and artefacts due to breathing and peristaltic movements, or the presence of gas into the intestines, 
may seriously affect the image quality.  On the other hand, the tail of pancreas in mice is closely 
adjacent to spleen and stomach, which are easily detectable in MRI, driving pancreas identification. 
We performed all MRI acquisition using parameters such as fat suppression filters, in order to 
minimize the interference of abdominal fat that is brilliant in MRI.  Moreover, slices thickness was 
maintained fixed on 1 mm without any distance factors, so that pancreas tissue could be 
differentiated from other tissues. All primary tumors were well detectable for sizes no less than 2 
mm; this size corresponds to a time interval from the surgery no shorter than one month from 
orthotopic injection. For this reason, earlier tumor development can’t be followed in our orthotopic 
models by MRI. At the same time, putative metastasis we found in small intestine and adhere on the 
liver surface of 9  mice injected with spheres; however, because of their small sizes and their 
location in the abdomen, they have been never individuated by MRI (Fig. 21; Fig. 35-36). 
  
Figure 35. MRI T1-weight of a orthotopic mouse model 30 days after injected with spheres growing 
cells; arrows indicate primary tumors. Picture (B): Putative metastasis in small intestine have been 
not identified in MRI sequence (Panel A). 
A 
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Figure 36. MRI T1-weight of a orthotopic mouse model 30 days after injected with spheres growing 
cells; liver is highlighted in green. Picture (B): Putative metastasis in liver have been not identified 
in MRI sequence (Panel A). 
MRI is necessary to identify the anatomical location of  primary tumors, to follow growths and to  
measure sizes  showing at the same time the shape of the developed  mass. It’s a crucial technique 
in small-animal imaging but is not sufficient, if used alone, for detection of small masses above all 
in difficult anatomical region such as abdomen cavity.  
 
4.9  Bioluminescence Imaging for the detection of small masses. 
Since MRI resulted useful but not sufficient for the follow up of the tumor development in our 
orthotopic models, we decided to focus the attention on a combined imaging system in order to 
individualize positively both primary tumors and putative metastasis. We chose to study the 
complementary roles of MRI, Bioluminescence imaging and Micro-US performing new orthotopic 
injections using Panc-1 cells transfected with the reporter gene Luciferase (Panc-1-Luc+ cells). The 
latter were injected in the pancreas of  twenty-three nude female mice according to the protocol 
described in section 3.3. Animals were divided in two groups: thirteen  were inoculated with 5*106 
Panc-1-Luc+ cells (Group one) and the other ten with 2*106 Panc-1-Luc+ cells (Group two). Cells 
were suspended in 60 µl in PBS containing 1% serum-free Matrigel (vol/vol). The negative control 
group was constituted by five mice which received only Matrigel (60 µl).  Five mice belonging to 
the Group one received cells suspended in RMPI serum-free instead of sterile PBS because we also 
wanted to evaluate the effect in term of tumor size progression of colture medium respect to PBS. 
A 
 
B 
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Before performing orthotopic injections using Panc-1-Luc+ cells, we tested in vitro their 
bioluminescence activity in presence of the substrate Luciferin. Since bioluminescence test in vitro 
had to be performed screening cells in their flask, in order to avoid interferences with the cell 
signals, emissions by flask plastic was analyze alone. Flasks used for cells cultures didn’t show 
auto-bioluminescence proprieties; moreover, Panc-1-Luc+ cells showed a strong bioluminescence 
activity (Fig. 37). 
   
Figure 37. Panc-1-Luc+ cells Bioluminescence test activity  in vitro: Flask plastic doesn’t emit 
light (A), so positivity shows in B is due to activity of firefly Luciferase (Luc) present in Panc-1 
transfected cells.  
Before beginning, we decided to inoculated 2*106 Panc-1-Luc+ cells in the flank of five nude mice 
in order to control their capability to grow in vivo and evaluated the emission of photons thought 
overlying tissue. Bioluminescence emission from tumors grown in the subcutaneous models were 
high and ground noise was very low (Fig. 38). 
  
Figure 38. Subcutaneous injection of Panc-1-Luc+ cells. In picture (A), subcutaneous mice model 
before Luciferin injection (acquisition “pre”); in (B), light emission from subcutaneous tumors 
(acquisition “post”). Arrows indicate subcutaneous tumors.  
A B 
A B 
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For all animals, we measured the Region of interest (ROI)  which corresponds to measures the 
signal intensity in a specified area of the Optical image. In that way, it is possible to estimate total 
photon flux from the point source coming from the selected area. We calculate for each mouse two 
ROIs: one comprised  whole abdominal area (ROI 1, the bigger one) and one drew also around light 
emission corresponding to the primary tumor (ROI 2, the smaller one). In this way, we obtained, 
from time to time, information about the total emission in that  mouse, due to primary tumor alone 
or in association with eventual supplementary masses, and information about the specific 
contribution to developing primary tumor in the total intensity of the emission signal (Fig. 39).  
Using a small selected ROI within the total abdominal area (smaller ROI), we made a correlation of 
whole tumors bioluminescence imaging and MRI for assessment of tumor size in mice. 
 
 
Figure 39. Two examples of selected ROI in an acquisition before (up) and after (down) the 
Luciferin injection, both in whole abdominal region and in the site of tumor growth.  
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4.10  Correlation of MRI, Ultrasound and Optical Imaging for monitoring tumor 
growth over time 
 
 4.10.1 First time-point, 30 days after surgery 
 
When Panc-1-Luc+ orthotopic injections were performed in each animal according the scheme 
described before, we decided to investigate tumors development and growth using MRI, 
Bioluminescence imaging and Ultrasound (US) fixing the first control 30 days after surgery. Then, 
we chose to repeat acquisitions for all mice every 30 days for no less than two times, up to animals 
showed good health. Imaging analysis were performed in a time-frame of three days for each time-
point in order to minimize differences in measured sizes and avoid to administer high doses of 
anesthetics at the same time. 
Findings obtained from the first in vivo imaging acquisitions one month after surgery showed 
clearly that US failed to visualize tumors which were too much smaller to be detect by our US 
probe (data not shown). Also Micro-MRI and Bioluminescence failed in the detection of such small 
masses whereas those larger were identified. At the first time-point acquisition, MRI detected  9/13 
mice belonging to the Group one, whereas only 1/10 mice of the Group two showed a measurable 
mass.  Bioluminescence imaging  resulted more accurate at the same time point: all mice (13/13) 
belonging to the first group had good light emissions, even if different to each other for intensity. 
Moreover, in three of them, apart from light emission by primary tumors developed within the 
pancreas, small light sources were detected in anatomical areas different from the pancreas itself. In 
the case of mice from the Group two, Optical imaging obtained positive sources from 5/10 mice 
(1:2), but in this case no little supplementary light emissions were found except to those derived 
from primary tumors (Fig. 40- 41- 42).   
Picture 40 (B) shows two mice belonging to the Group two represented in a sequence acquired 
during the same session: picture numbers 1, 2 and 3 concern to the three time-frames in which the 
acquisition is divided (0-5; 5-10; 10-15 minutes). Luciferin reaches its emission peak until 15 
minutes after its injection, then the last time-frame corresponds to the maximum in the Luciferin 
emission spectrum.   
Picture 40 (A) shows two of the mice of the Group one. Firstly, having received a high number of 
cells,  it’s evident that signals are stronger by comparison with the previous one. Moreover, in line 
with the Luciferin emission spectrum trend, it’s possible to appreciate an increase of spot intensities 
with the passing of time, especially in mouse on the right. The reverse rainbow color table in both 
images assigns violet to the lowest number on the array and  red to the highest number, and convert 
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numerical contents of scientific image  data (photon flux) into luminescent images acquired with an 
IVIS Imaging System. Pseudo-color associated-scale of values is increased considerably in mice of 
group one (B).  
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Figure 40.  In picture (A), two mice belonging to Group one; tumors show bright signals already at 
the first time-point. In (B), no tumor was detected in mouse on the left at the first time-point 
acquisition, one month after surgery. On contrary, the other one show a good emission. 
A. Group one, 5*106 Panc-1-Luc+ cells 
B. Group two, 2*106 Panc-1-Luc+ cells 
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Figure 41 and 42 show that there is a correlation between MRI and Optical imaging for the 
detection of primary tumors. One mouse doesn’t show light emission both in MRI and in Optical 
imaging (Fig 42 B). 
 
 
 
 
Figure 41. Two mice belonging to group one; smaller optical imaging picture in the center refers to 
picture 3 of Figure 40, (A). In both cases, MRI identified the two tumor masses (red rings). 
 
 
 
 
 
 
Figure 42. Two mice belonging to group two; smaller optical imaging picture in the center refers to 
picture 3 of Figure 40, (B). Only in mouse on the left, MRI identified the tumor masses (red ring). 
 
A. Group one, 5*106 Panc-1-Luc+ cells 
B. Group two, 2*106 Panc-1-Luc+ cells 
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 4.10.2 Second time-point, 60 days after surgery 
 
We firstly evaluated the tumors growth in Optical imaging and MRI, with attention to avoid to 
administer in the same day both anesthetics to the same animal. Increase in size of tumors was 
clearly visible in MRI, so that we decided to perform also acquisition with US at this time-point. 
MRI detected 12/13 mice of the Group one at this time-point, three mice in addition respect to 
previously acquisitions. In Optical imaging acquisitions, we obtained very good emissions from 
each mouse of the same group (13/13); moreover, supplementary light emissions probably 
corresponding to smaller tumor masses were detected in three mice, confirming what seen in the 
first acquisition session. An increase of detected masses was also seen in mice belonging to the 
Group two: MRI individualized 6/10 tumors, whereas Optical imaging was 8/10 (three in addition 
respect to the first time-point acquisitions), even if some of them had very low signals, without 
other light sources except from primary tumor. Once again, in this group, only one animal showed 
no detectable photons emission in Optical imaging and corresponded to one of the mice of group 
two never seen before in RMI (Fig. 43B and 45). 
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  Detail of the third acquisition time-frame 
A. Group one, 5*106 Panc-1-Luc+ cells 
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Figure 43. In picture (A), mice of group one; tumors show very bright signals at the second time-
point. A supplementary light emission appears in mouse on the left.  In (B), no tumor was detected 
in mouse on the right, as well in Imaging performed 30 days after surgery. On contrary, the other 
one shows a good emission. 
 
 
 
 
 
Figure 44.  Two mice belonging to group one; smaller optical imaging picture in the center refers 
to picture 3 of Figure 43, (A). In both cases, MRI identified the two tumor masses which were 
bigger than the one identified in the first time-point (red rings). 
 
 
B. Group two, 2*106 Panc-1-Luc+ cells 
A. Group one, 5*106 Panc-1-Luc+ cells 
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Figure 45. Two mice belonging to group two; smaller optical imaging picture in the center refers to 
picture 3 of Figure 43B.  MRI identified the tumor masses in mouse on the left (red ring). No tumor 
was detected,  for the second time, in mouse on the left (the same one than in Figures 38 and 41).  
 
 
Ultrasound acquisitions were performed without anesthetized mice. Since tumors began to be 
sizable in MRI, we expected to can see them also in US. Even if quickly and very convenient, 
detection of tumors was complicate by presence of gas in the intestine of mice. 10/13 tumors in 
mice belonging to the first group were individuated, and only 4/10 tumors in mice of the Group two 
were clearly visualized in US (Fig. 46).  
 
 
Figure 46. US images of the mouse already shown in Fig.ure 42A, on the right. Tumor mass is 
located between the two stars. 
 
B. Group two, 2*106 Panc-1-Luc+ cells 
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 A particular case in Group two 
 
As described before, MRI individualized 6/10 tumors from Group two, whereas Optical imaging 
was 8/10. However, one of two “negative” mice corresponded to a mouse that showed light 
emission at the first time-point. This particular case observed during the second acquisition of 
Optical imaging is described below in details. Summarizing, in this mouse we didn’t find visible 
masses in MRI at the first imaging session, but a good light emission was detected in Optical 
imaging at the same time (Fig. 47). The situation was reversed during the second imaging 
acquisition: in fact,  MRI and US indicated the presence of a tumor mass, even if small, but photons 
emission, already seen 30 days before, disappeared (Fig. 48). 
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Figure 47. Optical imaging and MRI, acquisition at time point one, 30 days after surgery: only 
Optical imaging detected tumor mass. 
Optical imaging I: tumor detected - mouse on the right 
MRI I:  NO mass detected  
75 
 
 
FB20100112105449_SEQ
 
 1
400
350
300
250
200
150
100
Color Bar
Min = 58
Max = 417
 2
 3
 
   
 
 
 
Figure 48. Optical imaging , US and  MRI, acquisition at time point two, 60 days after surgery: 
only MRI  and US detected tumor mass. 
Optical imaging II: NO tumor detected - mouse on the right 
MRI II:  tumor mass was detected  
US II:  tumor mass was detected  
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Knowing differences in sensibility between Optical imaging and MRI respect to the detection of 
small masses, findings resulting from the second time-point appeared immediately strange; in fact, 
since we had already seen emission light in the first session, we expected certainly to detect 
bioluminescence signals  in the second optical imaging session too, and perhaps, in MRI, but not 
the contrary.  In order to better understand what happened about this animal, we decided to repeat 
bioluminescence acquisition the day after, avoiding in this way to administer double dose of 
anesthetic during the same day. Luciferin is not toxic, so repeated administrations in short time 
don’t make negative effects on the animal. 
Figure 49 shows findings we obtained thanks to the repetition of optical imaging acquisition for that 
mouse. Bioluminescence signal was evident now. In conclusion, the number of tumor detected by 
bioluminescence imaging, for the Group two, was confirmed to be 9/10 mice. 
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Figure 49.  Repetition of optical imaging acquisition for one mouse belonging to Group two: the 
tumor, already detected by MRI, is evident now. 
 
 
 
 
Optical imaging REPETITION-II: tumor now detectable 
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 4.10.3 Third time-point, 90 days after surgery and necropsies. 
 
Three months after orthotopic injection of Panc-1-Luc+ cells, animals were imaged by each 
technique for the last time because first signs of suffering occurred.  Then, they were sacrificed and 
tumors processed for histological analysis. Tumors became very large so MRI individuated easily 
masses in all 13 mice belonging to group one (13/13); for the same reason, very high level of 
photons emission were detected during  Optical imaging acquisition (Fig. 50), so much that we had 
to repeat some acquisitions because such images contained saturated pixels. Moreover, an increase 
intensity of photons flux coming from supplementary sources was observed, even if they seem to 
come from different anatomical region respect to what observed in the previous finding. With 
regard to Group two, MRI detected 7/10 tumors, only one in addition respect to the second 
acquisition; with the regards to Optical imaging technique, results of the second time-point were 
confirmed (9/10, because one mouse never showed emission light).  
 
 
           
 
 
A. Group one 
5*106 
 Panc-1-Luc+ 
cells  
B. Group one 
5*106 
 Panc-1-Luc+ 
cells  
C. Group two 
2*106 
 Panc-1-Luc+ 
cells  
Figure 50. Last Optical imaging 
acquisition, three months after surgery. 
Picture (A) and (B) refers to animals 
belonging to Group One.  
(C) shows animals of the Group two; in 
particular, mouse on the right never 
showed the presence of tumor with any 
technique. 
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Tumors  in mice belonging to the Group one grew dramatically in the last month; their size and 
shape could be observed perfectly in the last MRI acquisitions. On the contrary, Ultrasound was not 
able to individualize all the tumors  of the Group one (8/13), in general because of the presence of 
acoustic impedance in the abdominal activity and because the low frequencies of US probe 
produces an insufficient resolution.  
Thanks  to high-quality MRI images, especially of those of Group one, and to the easy application 
for measuring tumors, we noticed that a sub-group within the Group one existed. In fact, five 
animals  in the group one showed tumors evidently bigger than the others (Fig. 51). They 
corresponded to animals which received Pan-1-Luc+ cells suspended in RPMI-serum free instead of 
sterile PBS. Probably, the presence of culture medium together with the Matrigel is able to assure 
major cell survival both before injection and once inoculated in the pancreas. Moreover, in spite of 
their sizes, these tumors seem not to have necrotic regions inside.  
 
Figure 51.  Differences in sizes between  tumor derived from Panc-1-Luc+ suspended  in PBS (A) 
and suspended  in RPMI serum-free (B). Images refer to last MRI few days before necropsies. 
 
All mice were sacrificed by cervical dislocation at the end of  the last images data capture. After the 
first macroscopic analysis, we took tumors, spleen, residual normal pancreas, small intestine.  
During necropsies, we often noticed the presence of small and with projections adhering to the 
small intestine, so we collected also some of them. In Figure 52, we report  a comparison between 
last acquisition of MRI, Optical imaging, US and necropsy relative to one the mice belonging to the 
Group one. We report also the same comparison but relative to the only mouse that never showed 
both bioluminescence activity and sizable masses in MRI and US. Histological analysis confirmed 
in this case that no tumors were present inside the pancreas, that appear normal closed to the spleen 
(Fig. 53); probably, in this case the problem was linked to surgery or cells survival rate, but surely  
not to in vivo imaging techniques.  
Cells in PBS/Matrigel  Cells in RPMI-serum free/Matrigel 
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Figure 52.  Optical imaging (A), MRI (B), US (C), tumor sample (D) and H&E staining of a mouse 
belonging from the Group one. All imaging techniques detected the tumor. Images refer to the third 
time-point acquisition. 
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Figure 53.  Optical imaging (A),  pancreas and spleen (B) and H&E staining relative to the mouse 
in which imaging technology have never found tumor. The histological analysis shows normal  
pancreas closed to the spleen. Details 2-3: Langerhans isle.  
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In few cases such as the one reported below regarding a mouse of the Group one, we observed a 
strict correspondence between Optical imaging and MRI in regard to the fact that primary tumor 
was divided into two parts; also US distinguished the two components thanks to the low depth of 
the smaller one. These findings were confirmed at the moment of necropsy (Fig.54).    
 
    
 
  
 
Figure 54. Correspondences between  all techniques and final necropsy for a mouse of the Group 
one.  
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4.11 Analysis of Supplementary masses 
 
In three cases belonging to the Group one we founded, already in the first Optical imaging 
acquisitions, 30 days after surgery, supplementary small light spots coming from anatomical regions 
different from the pancreas, and  far to the primary tumor emissions. Because of Luciferin is the 
substrate of Luciferase, present only in the tumor cells we inoculated, and doesn’t emit light by 
itself, we supposed these light spots could be putative small metastasis. These supplementary light 
spots were founded also in the second and the third  Optical imaging acquisition, but never by the 
other two imaging techniques we used. Moreover, supplementary emissions are localized in 
different regions moving from the first , the second and the third acquisitions.  However, at the time 
of necropsy, we found evident small tumor masses only in one of the three mice involved in these 
supplementary study (Fig. 54). On the other hand, checking through the small intestine of these 
latter, we noticed the presence of small white protuberances adhering to the intestine of all the mice 
(Fig. 55). We collected that intestine portions to perform H&E.  
 
Figure 54. Small tumor masses found in the abdominal cavity of one of the three mice which 
presented supplementary light spots (A: acquisition at third time-point). Arrows in C show them, 
whereas black rectangular indicates the masses we collected for H&E staining. 
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Figure 55.  A part of  the primary tumor, no evident supplementary masses were found. We noticed 
the presence of small white protuberances adhering to the intestine (red rings). 
 
H&E staining confirmed that small masses collected from  mouse showed in Figure 54 were 
composed by tumor cells (Fig. 56), whereas no tumor cells were found in the other two mice. 
Protuberances present in the intestine of the latter were identified as small intestinal intraepithelial 
lymphocytes (Fig. 57-58), lymphoid nodules normally present in the intestine of mice. Probably 
they became bigger following to general inflammation stimuli, showing foreign body granuloma 
characteristics, clearly distinguishable from the surrounding normal tissue. Histologically, it is 
composed of macrophages that have differentiated into large cells with indistinct cell boundaries 
called cells epitheloid. 
Some of these may fuse with each other to give rise to the  multinucleate cells  called "foreign body 
giant cells" in which typically nuclei are distributed randomly all over its cytoplasm.  No tumor 
cells can be detected inside these nodules.  Finally, we found putative metastasis in only one 
animal, even if emission spots were detected in other two animals since the first Optical imaging 
acquisition. In all other mice, in spite of very big sizes of the developed tumour, light signals 
corresponded always to the presence of the primary tumors.  
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Figure 56. In (A), a detail of Fig.ure 54: small masses collected from the small intestine of the 
animal. H&E staining  (B, C and D, images Aperio 1X, 4X and 20X respectively) confirmed that 
they were tumors. 
 
 
 
 
Figure 57. Small intestinal intraepithelial lymphocytes found in one of the two mice that showed 
light emission but not supplementary visible small masses (A, Aperio 1X; B, Aperio 5X). 
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Figure 58. Small intestinal intraepithelial lymphocytes found in the other mouse that showed light 
emission but not supplementary visible small masses (A, Aperio 1X; B, Aperio 5X;C, Aperio 20X). 
 
Summarizing, even if light signals from supplementary masses were detected in three mice, we 
found small tumor masses in the intestine of only one of them. Trying to get the fact, we studied the 
emission light trend relative to the two mice with intraepithelial lymphocytes stations. We 
considered both total emission coming from all the abdominal area (e.g., see bigger ROI in figure 
39) and the emission relative to only primary tumor (e.g., see smaller ROI in figure 39), in order to 
appreciate the differences and understand what was the contribution of photons emission of small 
masses considered alone. Looking to the flux values calculated considering primary tumors alone 
(corresponding to the smaller ROI) and the total flux values corresponding to the total abdominal 
emission (bigger ROI), we observed that there are not significative differences between them.  
These findings suggests that there is not contribution in light emission coming from supplementary 
small masses. Probably, some very little tumor cells aggregations were present in the abdominal 
cavity of those two mice, so small that it was hard to see them at the moment of necropsies, but 
their number was sufficient to emit a light signal detectable by our Optical imaging devise. 
However, a little but significative difference was found analyzing the flux values relative to the 
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smaller and the bigger ROI acquired from the mouse in which visible putative metastasis were 
found.  
 
 
 
4.12  More information from MRI and Bioluminescence imaging 
 
Other information could be extracted comparing MRI and Optical Imaging results in a very easy 
way. Looking to the photon flux values  from the first to the last acquisition, we expected to see that  
they increase, due to the presence of  more tumor cells which oxidize the Luciferin substrate. In the 
majority of the cases, especially in mice belonging from the Group one, the bioluminescence 
activity increased  in a considerable way. If necrotic regions were present within the expanding 
tumor mass, bioluminescence activity should decrease because only vital cells can oxidize the 
Luciferin.  It was not our case, as shown in Figure 59. MRI can supports this analysis in vivo, 
thanks to the fact that necrotic regions appear like more “brilliant” focal areas, and prevent the 
diffusion of the contrast agents. In fact, the homogeneous diffusion of the contrast agent 
Gadolinium in the tumor mass, as shown in the  MRI sequence in Fig. 59, confirmed this finding. 
Tumors in our models were characterized by very low necrotic parts, in spite of their big sizes (Fig. 
59).  
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Figure 59.  In Panel A, correspondences between an MRI image and Bioluminescence activity of a 
mouse belonging to the Group One. Histology confirmed what the tumor didn’t contain necrotic 
regions. In Panel B, the same mouse was imaged in MRI using contrast agent Gadolinium 
(sequence from 1 to 5):pictures 1,2,3 showed tumor before diffusion of contrast agent, whereas 
pictures 4 and 5 indicate that the complete diffusion of Gadolinium in the tumor mass. 
 
 
 
4.13 3D Reconstruction individualizes location of putative metastasis  
 
We performed 3D reconstruction on one of the animal showed in figure 55, in which we didn’t 
found putative metastasis even if supplementary light emissions were detected. Thanks to the 
Living Image 3D Analysis Package ( an image analysis application for  viewing  and analyzing  
image data acquired by the IVIS® Imaging System Series), we was able to collocate the 
supplementary light sources, as shown in figure 60. 
The photograph of our mouse is visualized as a tridimensional subject. T his application consents to 
choose which organs have to be introduced in the transparent body of our mouse. We chose to 
visualize liver, small intestine, and the pancreas. Brain was inserted in order to orientate the mouse 
body in the space.  Looking to the reconstructions, two light sources are clearly visible and are 
located distant  far from the primary  tumor. They are shown as two voxels  (tridimensional pixels) 
collocated in correspondence of the small intestine.  
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Figure 60. 3D Reconstruction of the mouse showed in showed in Fig. 55. In (A), arrows indicate 
the two voxel corresponding to the supplementary light sources. Ring indicate the primary tumor 
emission. Brain in colored in white, pancreas is yellow, small intestine is pale blue and the liver is 
red. In (B), the same image but without the liver. 
 
A 
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Moving the body in the 3D spaces (fig.61), it is possible to see better that emission of these two 
light sources come from the small intestine. So, it is believable that some tumor cells, in a sufficient 
number to emit a detectable light signal, are organized in small intestine, even if they cannot be 
seen to a naked eye. 
 
 
 
Figure 61. In (A), only the pancreas have been inserted.  Closed to it, light emission coming from 
the primary tumor. In (B), rotation of the 3D model shows the depth of supplementary  light 
sources.  
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5. Discussion  
Pancreatic cancer remains one  of the most lethal malignancies and metastatic pancreatic carcinoma 
represents a bleak prognosis for the patient. Late diagnosis together with the rapid disease 
progression and poor responses  to available therapies are the causes of the high mortality linked to 
this disease. Even if, in recent years, many efforts have been made to better understand the genetic 
mutations involved, the reasons of the inefficient drug delivery, the cellular signaling and novel 
biomarkers specific of pancreatic cancer, the final resolution doesn’t seems imminent yet. 
The cancer stem cells (CSC) hypothesis, identifying these cells as the key of tumor development, 
progression and metastasis, offers the opportunities to develop therapies which actually enhance 
survival rate and life quality. However, the in vitro studies of cultured tumor cells have some 
limitations because they will never resemble what happens in the development and progression of 
the tumor within living organisms. So, the better way to intersect together the need of increase our 
pancreatic cancer stem cells knowledge without moving away from all the mechanisms of a living 
organism is to establish a pancreatic mouse model in which behavior of pancreatic CSC can be 
study directly and on which novel therapies can be test.  
Stem-like proprieties of sphere growing Panc-1 cells, selected starting from Panc-1 adherent cell 
line, was already demonstrated in our laboratory. Briefly, Panc-1 adherent cells were cultured under 
specific stem cell promoting culture conditions. The use of a serum-free medium, supplemented 
with growth factors, which are also present in the pancreatic microenvironment, resulted in sphere-
growing cells. The presence of membrane markers expression CD24, CD44 and ESA, 
multipotentiality and stem functionalities, together with an increased expression of markers of 
active Hedgehog signaling, confirmed the typical stem features of spheres growing cells. The 
chemoresistance of the Panc-1 sphere-growing vs adherent cells was assessed by incubating the 
cells with increasing concentrations of Gemcitabine (GEM). 10% of the sphere population survived 
to Gemcitabine at high doses, confirming the observation of Gou et al. who reported that Panc- 1 
spheres contain a chemoresistant side population of 15%.   
These preliminary results suggested that Panc-1 spheres might be a clinically more reliable model 
system to study the stem-like cell population than Panc-1 adherent cells. 
On the basis of these findings, in the current study, we focused on the behavior of spheres growing  
cells when injected in the  pancreas of nude mice; for this goal, we decided to follow tumor growth 
in MRI. Moreover, following some troubles linked to difficulties to see clearly small masses in 
abdomen cavity by MRI,  we decided to take an interest also to other small-animal imaging 
modalities capable of following tumor development and progression in vivo  in a rapid, fast and 
above all safely way.   
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Firstly, we demonstrated that spheres grow faster, when injected in the pancreas of nude mice, than 
the adherent counterpart, and tumor they generated were bigger than those obtained in the latter. 
From the histological point of view, H&E staining demonstrated that sphere growing tumors 
established in nude mice showed more irregular mitotic figures than adherent cell derived tumors. 
Moreover, adherent cells demonstrated a more organized architecture, whereas the spheres 
generated a more dysplastic tumour structure. Moreover, immunostaining for CK7, a marker of 
differentiation commonly used in diagnostic of epithelial tumors, showed a great difference 
between the two kind of tumors: we observed a strong positivity of adherent derived tumor for CK 
marker, whereas spheres resulted totally negative.  
Taken together these findings demonstrated that, starting from  the total pool of adherent Panc-1 
cells,  we selected the less differentiated subset of cells, CK negative,  characterized also by 
elevated mitotic activities that could explain the fact that tumor derived from spheres grow faster 
than those derived from adherent cells. 
Putative metastasis were found in 9/10 mice inoculated with spheres growing Panc-1 cells, in 
particular in the liver and within small intestine, and in 1/10  inoculated with adherent Panc-1 cells. 
These findings suggested that spheres cells are more aggressive than adherent cells when inoculated 
in the orthotopic site.  
Because of numerous observations support the idea that Epithelial to Mesenchymal transition 
(EMT)  has a central role in tumor progression, we studied the EMT markers (E-Cadherin, 
Vimentin, S100A4, Twist and Slug) expression in spheres Panc-1 cells and adherent Panc-1 cells in 
vitro and then in tumors derived from spheres growing Panc-1 and adherent Panc-1 cells, after 
subcutaneous and orthotopic injections. In these EMT immunohistochemical study, we also 
included putative metastasis we found in 5 animals inoculated with spheres growing cells.  
Our findings demonstrated that EMT markers expression was higher in spheres derived tumors  
developed in the orthotopic site compared with all the other cases we considered. Expression of the 
EMT markers in primary spheres derived tumors and putative metastasis was almost comparable, 
but anyway  higher respect to expression the same cells in vitro or in  subcutaneous tumors.  
The acquisition of Mesenchymal markers from spheres cells, particularly stronger when they grow 
in vivo in the orthotopic site, may be the key that could explain the aggressiveness of spheres 
compared to adherent cells. During EMT, invasion epithelial tumor cell degrade their basement 
membrane and migrate by alternating phases of adhesion and detachment from extracellular matrix 
(ECM) and Integrins are the main receptors involved in binding and in response to ECM. For this 
reason, as a future development of EMT study in spheres growing Panc-1 cells, we will study  the 
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role of Integrins both in spheres growing cells in vitro and in tumors derived from them after 
orthotopic injection. 
The generation of a pancreatic mouse model in which only spheres growing cells are used to induce 
tumor formation acquired considerable importance especially in the contest of in vivo testing of 
novel drugs. Therapies available today, such as Gemcitabine, are not able to kill this “stem-like” 
subset of cells which may  coincide with the chemoresistant subpopulation within the 
heterogeneous total pool of tumor cells; for this reason, survival cells can reestablish the tumor. 
As already said, only thanks to necropsies, we found putative metastasis in 9/10 mice inoculated 
with spheres growing cells but these small masses were never identified during MRI acquisitions. 
MRI pancreas imaging in mice is particularly difficult because this organ, extremely soft, is 
immediately adjacent to the gut; moreover, artifacts due to the presence of gas within the intestine, 
such as breathing movements of the mouse, really may compromise the images quality. However, 
MRI is useful when tumors achieve considerable sizes, because it gives us the possibility to 
measure the tumor widths, identifying shape and anatomical location of the mass. So, the 
identifications of small imaging techniques capable to detect precisely possible decreases in primary 
tumor sizes and, at the same time, able to identify metastasis, following their “destiny”  during 
drugs therapies, is a need that cannot be neglected. Considering difficulties we encountered using 
MRI, before the beginning of any novel test compounds in vivo on our spheres-derived mice 
models, we decided to actuate in parallel the study of other two imaging techniques for overcoming 
limits of MRI :  Optical imaging based on Bioluminescence and Ultrasound (US). 
We used Panc-1 cells transfected with the gene reporter Luciferase (Luc), performing novel 
orthotopic injections in 23 nude mice. In particular, mice were divided into two groups: the first one 
included mice (13, Group one) injected with 5*106 Panc-1- Luc+ cells; the second one comprised 
mice (10, Group two) injected with 2*106  Panc-1- Luc+ cells. We performed the in vivo imaging 
acquisitions, with all three techniques, 30, 60 and 90 days after surgeries.  
The first time acquisition showed that MRI detected 9/13 tumors in the  Group one and 1/10 in the 
Group two; Optical Imaging was 13/13 for the first and 5/5 for the second group. No tumors were 
detected using US. These first finding are in line with we expected: tumors in Group one were 
bigger than those in Group two, simply because they derived from a different starting number of 
inoculated cells. Since Optical imaging has higher sensibility respect to MRI, all tumors were 
individuated, whereas 4 tumors were too smaller to be seen in MRI. US probe we used (16 MHz) 
probably was not sufficient for detecting tumors at this time point. Measures at the second time 
point, 60 days after surgery, the number of tumors detected in MRI rose to 12/13 for the Group one 
and to 6/10 for the Group two. US individualized 10/13 and 4/10 for the first and the second group 
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respectively. Tumors of the Group one seen in Optical imaging remained fixed to 13/13, whereas 
the number of emissions light detected from the Group two increased from 5 to 8. However, 
curiously, one of the two mice resulting “negative” at this time point corresponded to one of those 
in which light emission for clearly detectable at the first Optical imaging acquisition. Because of 
this technique may show false negative results but not false positive one, we believed in the light 
spot seen at the first time. Moreover, at the second  time point, tumor was clearly visible both in 
MRI and in US.  
Light emission appears only if Luciferin is oxidized by Luciferase which is present only in 
transfected tumor cells we inoculated. So, light emission corresponded to the fact that Luciferase-
Luciferin reaction is happened. Since Luciferin has not bioluminescence activity by itself, we 
excluded that the light source seen at the first acquisition was  due to substrate accumulation in such 
tissues different from the tumor mass. We repeated the acquisition the day after, in order to avoid 
side effects for excess of inhaled  isofluorane. Interestly, after this repetition, the light signals 
coming from primary tumor was detectable now. Thinking to the reason why emission disappeared 
at the second time point in this animal, we concluded that probably a mistake in the Luciferin 
injection occurred. Protocols of Optical Imaging suggest intraperitoneally injection of Luciferin; 
moreover, it well know that the emission peak is reached more or less 15 minutes after Luciferin is 
inoculated in the abdominal cavity; this is the reason why programmed acquisitions time of 
Bioluminescence signals is divided into three time-point (0-5, 5-10, 10-15 minutes, after Luciferin 
injection), a time-frame that corresponds to the maximum Luciferin emission time. If injection is 
performed in the wrong way, involving for example an intestinal handle, the diffusion of Luciferin 
may be compromised and slowed down, Luciferase cannot oxidize its substrate in time, because not 
available, and when programmed acquisition time is completed, no light emission can be detected.   
At the third and last time-point, 60 days after surgery, 13/13 animals belonging to the Group one 
were detectable using both Optical Imaging and MRI because tumors became too big (till 13 mm). 
However, these big sizes became a limit for US sensibility: US failed in detecting  such big tumors,  
in general because of the presence of acoustic impedance in the abdominal activity and also because 
the low frequencies of US probe of our devise produced an insufficient resolution. With regard to 
the Group two, MRI detected 7/10 tumor masses against 9/10 seen in Optical imaging. One mouse 
belonging to the Group two never display the tumor mass. 
In addition to these finding, the comparison between all three imaging techniques gives as other 
important results. In fact, since from the first acquisition session, 30 days after surgery, three 
animals belonging to the first group displayed more than one light sources in Optical imaging. 
These supplementary small masses were not visualized in MRI or US. We focused our attention on 
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these small masses, just because difficulties in detection of putative metastasis in MRI was the 
reason why we decided to deepen the imaging issue in the current study. From the first to the 
second time-frame, the number of mice presenting supplementary masses was the same (3); 
however, we immediately noticed that the location of the light spots was changed. Since one of the 
disadvantages of Optical imaging is that light sources cannot by collocated precisely in the 
anatomical regions from which they come from, it was not possible to speak about liver or intestinal 
masses. The fact that their positions changed from an acquisition to the next one suggested that 
probably emitting small masses may move following the intestinal movements. However, as in the 
case of the mouse on which Optical imaging acquisition was performed twice, the fact that an 
emission was detected meant that such tumoral Luciferase+ cells emitted.  Surprisingly,  at the time 
of necropsies, evident small tumor masses were found only in one of these three mice, contrary to 
what we expected: these masses, scattered within the abdominal cavity, were collected for 
histological analysis. In the  other 2 mice, small white protuberances were detected on the surface of 
small intestine; we collected them believing they may coincide to small tumor cells aggregations, 
but histological analysis identified those protuberances as small intestinal intraepithelial 
lymphocytes stations, and no tumors cells were found within them. Intestinal intraepithelial 
lymphocytes stations are natural lymphocytes aggregations present in the gut of mice: probably, 
they became bigger following general inflammatory reaction, resembling small tumor masses to the 
naked eye.  
We noticed that there is not contributions in light emission coming from supplementary small 
masses in the two mice with small intraephitelial lymphocytes aggregations. Probably, some very 
little tumor cells aggregations were present in the abdominal cavity of those two mice, so small that 
it was hard to see them at the moment of necropsies, but their number was sufficient to emit a light 
signal detectable by our Optical imaging devise. A possible solution to overcome this troubles may 
be to let small masses become bigger, but this solution implicates that primary tumor reaches sizes 
incompatible with the life of the animal.  
Another possible solution contemplate the use of Fluorescence instead of Bioluminescence if we 
want to perform a guided necropsy. Fluorescence imaging uses external dyes or fluorescent markers 
which are either molecules that absorb electromagnetic energy in the near-infrared region or the 
new emerging class know as quantum dots. Even if fluorescence imaging requires the addition of an 
external light source to obtain a spectrum of the light emitted, it has the advantage to be detectable 
in non living animals. It is possible to perform an optical imaging acquisition before the animal is 
sacrificed; then, once the abdominal cavity is open, we can repeat the acquisition using the same 
fluorescent emission, but seeing directly from which organs the emission comes to. Also 
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combination of both optical imaging techniques, in the same animal, is possible. In fact, we are 
going to perform a double stable transfected pancreatic CSCs, expressing both Luciferase and the  
Red fluorescence protein (RFP). 
Finally, our finding demonstrated the need of using both MRI and Optical imaging for the detection 
of tumor masses in small animals. The use of US may be very practice and economic because no 
anesthetics and particular preparations of animals are required; however, it is necessary to have at 
our disposal high frequencies US probes, otherwise imaging in small animal, especially in the 
abdomen cavity, is very complicate. MRI and Optical imaging are complementary techniques of 
monitoring tumor progression and, used together,  they acquire much more importance  for 
monitoring tumor and metastasis response to treatments.  
We suggest an “Imaging protocol” in which MRI, US and Optical imaging are combined together in 
order to follow the orthotopic tumor growth in each moment of its development. In the earlier faces 
of tumor developments, during the first month after the surgery, Bioluminescence Imaging may be 
used in combination with high frequencies-US, since the latter is faster and relative economic if 
compared with MRI. When tumor are detectable in high-frequencies US, the following imaging 
time-frame may include MRI instead of US, in order to better appreciate tumors shape and size. 
Then, when tumors reach big sizes, and putative metastasis may be present, MRI should be use in 
combination with bioluminescence and fluorescence imaging, adding the latter optical imaging 
modality for the  detection of micrometastasis.    
In order to putting into action all findings of this study , selection of  spheres growing cells starting 
from adherent Panc-1 Luc+ cells is ongoing. So, as a future development of this work, we want to 
repeat the orthotopic injections in a bigger number of mice but using spheres Luc+ cells. In this 
way, we hope to obtain a mouse model of pancreatic cancer in which tumor and putative metastasis, 
enriched in tumor stem-like cells, are easily detectable thanks to the combined imaging approach. 
Moreover, we want to delve the study of metastatic mechanisms in our model. Another very interest 
evolution of the present research required the  study of tumors interstitial fluid pressure (IFP). 
Tumors develop elevated IFP during growth above all because of increased fluid permeability of the 
microvascular network and lack of functioning lymphatic vessels [34]. Elevated IFP may lead to 
poor tumor uptake of chemotherapeutic agents, and so resistance to treatment. Novel techniques in 
small imaging animal, such as Dynamic contrast-enhanced magnetic resonance imaging, are a 
powerful tool for investigating this important biological aspect. Linking together, thanks to the use 
of our mouse model,  the study of IFP with the investigation of the crucial role of CSCs in cancer 
development, we hope to clarify many obscure aspects of pancreatic cancer development and 
progression.  
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Our findings have demonstrated that the pancreatic cancer spheres are more than just cancer stem-
like cells. In addition, as these sphere-growing cells can be maintained relatively easily we have 
also generated a cell line-derived pancreatic cancer model that demonstrates characteristics of the 
clinically-relevant tumour. This cell system might be very useful to further the understanding of 
certain aspects of pancreatic cancer and could also be employed to screen compounds for 
therapeutic intervention, both in vitro and in vivo. When our models will be establish, they may be 
used for the testing of novel compounds specifically designed  to target  this stem-like 
compartment, resistant to standard chemotherapies. A combined imaging approach in this contest 
become extremely important, in order to follow decrease in primary tumor sizes, using MRI and 
US, and metastasis progression, using Optical imaging devises. 
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